GENERAL

CONTENTS Sections Definitions 1 Eligible Persons 2 Trillium Program 3-8.-10 Conditions for Designation of Listed Drug Products 11-12.0.2 Conditions to Continue to be a Designated Listed Drug Product 12.1 Establishing Criteria 12.2 Amounts Paid by Executive Officer 13-17 Limits on Amounts Paid by Executive Officer 18-20 Co-payment 20.1-20.5 Amount Charged to Person Other Than Executive Officer 21-22 Miscellaneous 23-30 Schedule 2 Definitions 1. (1) In this Regulation, “biologic drug product” means a drug derived from living organisms or their cells; (“produit médicamenteux biologique”) “biosimilar product” means a biologic drug product that has been approved for sale in Canada by Health Canada based on information comparing the biosimilar product to an original biologic product; (“produit biosimilaire”) “drug cost amount” means the quantity of a drug product multiplied by the drug benefit price of the drug product; (“coût indiqué du médicament”) “extemporaneous preparation” means a drug or combination of drugs prepared or compounded in a pharmacy according to a prescription; (“médicament préparé extemporanément”) “generic line extension drug product” means a drug product with the same active ingredient or ingredients in the same or similar dosage form as an original product, but in a strength for which no original product exists; (“produit médicamenteux générique comportant une extension de gamme”) “Ministry” means the Ministry of Health and Long-Term Care; (“ministère”) “modified release dosage form” means a dosage form of a product that is formulated to control the level of the drug in the blood over a shorter or longer period of time than a conventional dosage form; (“forme posologique à libération modifiée”) “original biologic product” means the original source of a biologic drug product in a particular strength and dosage form; (“produit biologique d’origine”) “original product” means the original source of a drug product in a particular strength and dosage form; (“produit d’origine”) “section 20.2 maximum co-payment” means the maximum co-payment determined in accordance with the rules set out in subsection 20.2 (4); (“quote-part maximale prévue à l’article 20.2”) “spouse” means a person, (a) to whom the person is married, or (b) with whom the person is living in a conjugal relationship outside marriage, if the two persons, (i) have cohabited for at least one year, (ii) are together the parents of a child, or (iii) have together entered into a cohabitation agreement under section 53 of the Family Law Act; (“conjoint”) “unit” means a gram, millilitre, tablet, capsule or other appropriate unit of a listed drug product in a particular dosage form and strength. (“unité”) O. Reg. 201/96, s. 1; O. Reg. 324/96, s. 1; O. Reg. 336/96, s. 1; O. Reg. 375/96, s. 1; O. Reg. 508/96, s. 1 (1); O. Reg. 110/97, s. 1; O. Reg. 299/97, s. 1; O. Reg. 612/98, s. 1; O. Reg. 72/99, s. 1; O. Reg. 332/99, s. 1; O. Reg. 401/99, s. 1; O. Reg. 588/99, s. 1; O. Reg. 69/00, s. 1; O. Reg. 202/00, s. 1 (1); O. Reg. 366/00, s. 1; O. Reg. 584/00, s. 1; O. Reg. 16/01, s. 1; O. Reg. 172/01, s. 1 (1); O. Reg. 358/01, s. 1; O. Reg. 64/02, s. 1; O. Reg. 214/02, s. 1; O. Reg. 395/02, s. 1; O. Reg. 88/03, s. 1; O. Reg. 334/03, s. 1; O. Reg. 60/04, s. 1; O. Reg. 184/04, s. 1; O. Reg. 321/04, s. 1; O. Reg. 12/05, s. 1; O. Reg. 191/05, s. 1; O. Reg. 334/05, s. 1; O. Reg. 484/05, s. 1 (1); O. Reg. 645/05, s. 1 (1); O. Reg. 55/06, s. 1 (1); O. Reg. 202/06, s. 1; O. Reg. 459/06, s. 1 (1, 2); O. Reg. 320/07, s. 1; O. Reg. 436/19, s. 1; O. Reg. 211/20, s. 1; O. Reg. 97/26, s. 1. (1.1) The functions and powers of the executive officer set out in subsection 1.1 (2) of the Act include the power, (a) to hold competitions for the purpose of selecting drug products that may be listed or continue to be listed as designated drug products on the Formulary or for any other purpose under the Act; (b) to use the results of such competitions in exercising any of the executive officer’s powers under the Act, including designating or continuing to designate a drug product as a listed drug product under section 19 of the Act or removing such a designation under section 20 of the Act; and (c) to enter into agreements that contain, among other things, provisions with respect to volume discounts and payments to the Minister of Finance. O. Reg. 356/08, s. 1. (1.2) The executive officer shall not, under section 16 of the Act, make the Act apply in respect of a drug that is a drug product described in subsection 12 (9) of this Regulation, unless the conditions set out in that subsection are met. O. Reg. 20/13, s. 1. (2) For the purposes of subsection 1 (2) of the Act, “therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are considered to be therapeutically equivalent, without authorization from a person authorized to prescribe drugs within the scope of his or her practice of a health profession. O. Reg. 459/06, s. 1 (3). (3) The executive officer may enter into agreements for the purposes of carrying out his or her functions under clause 1.1 (2) (a) of the Act. O. Reg. 459/06, s. 1 (3). (4) The executive officer may, in writing, delegate his or her authority under clause 1.1 (2) (c), (f) or (g) of the Act or subsection 1 (3) of this Regulation to any person employed in the Ministry. O. Reg. 459/06, s. 1 (3). (5) For greater clarity, the power of the executive officer under clause 1.1 (2) (f) of the Act to negotiate agreements includes the power to enter into such agreements that have been negotiated. O. Reg. 459/06, s. 1 (3). (6) Revoked: O. Reg. 220/10, s. 1 (2). (7) Revoked: O. Reg. 797/21, s. 1. (8) For greater certainty, a benefit provided as a professional allowance before July 1, 2010 is a rebate and is not a professional allowance unless the manufacturer providing the benefit and the person receiving it report to the executive officer the amount of professional allowance paid or received in the same manner as provided in Schedule 3 of this Regulation as it read before July 1, 2010. O. Reg. 220/10, s. 1 (3). (9), (10) Revoked: O. Reg. 220/10, s. 1 (3). (11) For the purposes of section 11.5 of the Act, a “rebate” does not include the value of a benefit that is provided in accordance with ordinary commercial terms that meet all of the following conditions: 1. The benefit is provided in the ordinary course of business in the supply chain system of listed drug products that are designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act between any of a manufacturer, a wholesaler, an operator of a pharmacy or a company that owns, operates or franchises pharmacies. 2. The value of the benefit is set out in a written agreement between any of a manufacturer, a wholesaler, an operator of a pharmacy and a company that owns, operates or franchises pharmacies. 3. The benefit relates to an ordinary commercial relationship that is any of the following: i. A prompt payment discount. ii. A volume discount. iii. A distribution service fee. 4. Revoked: O. Reg. 434/19, s. 1. 5. A person who receives the benefit reports to the executive officer, if required by the executive officer to do so, the net selling price of the drug products representing the drug benefit price less the value of the benefits received. O. Reg. 220/10, s. 1 (4); O. Reg. 434/19, s. 1. (12) For the purposes of section 11.5 of the Act, a “rebate” does not include the value of a benefit provided in accordance with ordinary commercial terms with respect to a listed drug product that is not interchangeable where the ordinary commercial terms are a discount for prompt payment. O. Reg. 220/10, s. 1 (4). Eligible Persons 2. (1) Subject to subsections (2) and (3), the following classes of persons who are insured persons under the Health Insurance Act are designated as eligible classes of persons for the purposes of section 2 of the Act: 1. Revoked: O. Reg. 398/22, s. 1 (1). 2. Persons who reside in homes licensed under section 5 of the Homes for Special Care Act. 3. Persons who are eligible for a pension under Part I of the Old Age Security Act (Canada). 3.1 Persons who are under 25 years of age and who do not have a private plan. 4. Persons who have attained 65 years of age. 5. Residents of long-term care homes under the Fixing Long-Term Care Act, 2021. 6. Persons who reside in homes that are part of the program of the Ministry known as the “Community Homes for Opportunity” program. 7. Revoked: O. Reg. 104/10, s. 1 (2). O. Reg. 201/96, s. 2 (1); O. Reg. 252/09, s. 1; O. Reg. 104/10, s. 1; O. Reg. 115/17, s. 1; O. Reg. 347/17, s. 1; O. Reg. 518/17, s. 1; O. Reg. 17/19, s. 1 (1); O. Reg. 309/22, s. 1; O. Reg. 398/22, s. 1 (1). (1.1) Revoked: O. Reg. 17/19, s. 1 (2). (2) A person is not a member of the class of persons referred to in paragraph 3 of subsection (1) until the first day of the month for which the person first receives payment of the pension. O. Reg. 201/96, s. 2 (2). (2.1) For the purposes of paragraph 3.1 of subsection (1), “private plan” means an employer, group or individual plan, program or account, however described, that could provide coverage for drug products, including the provision of funding that could be used to pay for drug products, regardless of the following: 1. Whether the drug product that could be eligible for coverage under the private plan is a drug product that has been prescribed for the person who has the plan and which the person is asking to be dispensed. 2. Whether the person who has the private plan or any other person is required to pay a premium, co-payment, deductible or other expense. 3. Whether the person who has the private plan has exhausted their entitlement under the plan. O. Reg. 17/19, s. 1 (3). (2.2) For the purposes of paragraph 3.1 of subsection (1), a person is considered to have a private plan if they are in any way captured by the plan, including, without being limited to, being captured as a named insured, an unnamed insured or an additional insured. O. Reg. 17/19, s. 1 (3). (3) A person is not a member of the class of persons referred to in paragraph 4 of subsection (1) until the latest of, (a) the first day of the month following the month the person attains 65 years of age; (b) the day that is five years earlier than the day the executive officer receives all the information required by the executive officer to confirm that the person has attained 65 years of age and that the person has been an insured person under the Health Insurance Act since the beginning of the five-year period; and (c) the day the person becomes an insured person under the Health Insurance Act. O. Reg. 201/96, s. 2 (3); O. Reg. 459/06, s. 2 (1). (4) In addition to the classes listed in subsection (1), the following classes of persons are designated as eligible classes of persons for the purposes of section 2 of the Act: 1. Persons who are receiving a professional service within the meaning of Ontario Regulation 187/22 (Home and Community Care Services) made under the Connecting Care Act, 2019 that is provided by a health service provider or an Ontario Health Team, other than training. 2. Persons who are receiving a service that is substantially equivalent to a service described in paragraph 1 and that is provided by an Indigenous organization that has entered into an agreement pursuant to paragraph 4.1 of subsection 6 (1) of the Ministry of Health and Long-Term Care Act. O. Reg. 398/22, s. 1 (2). Trillium Program 3. (0.1) In this section and in sections 4, 4.1 and 4.2, “fiscal period” means the 12-month period that begins on August 1 of every year and ends on the following July 31; (“exercice”) “quarter” means, in relation to a fiscal period, a three-month period that begins on August 1, November 1, February 1 or May 1. (“trimestre”) O. Reg. 374/99, s. 1 (1). (1) In addition to the classes listed in subsections 2 (1) and (4), persons who meet the following qualifications are designated as an eligible class of persons for the purposes of section 2 of the Act: 1. A person must be an insured person under the Health Insurance Act. 2. A person must be a member of a household unit whose members have collectively spent, in any quarter of a fiscal period, the amount determined in sections 4, 4.1 and 4.2, or more, on allowable expenses. 3. In order to become eligible, an application to become enrolled must be made to the executive officer on behalf of the person’s household unit and the executive officer must be satisfied that the members of the household unit have collectively spent the amount determined in accordance with sections 4, 4.1 and 4.2, or more, on allowable expenses in any quarter in a fiscal period. O. Reg. 201/96, s. 3 (1); O. Reg. 83/98, s. 1 (2); O. Reg. 374/99, s. 1 (2); O. Reg. 69/00, s. 2 (1, 2); O. Reg. 156/05, s. 1 (1); O. Reg. 459/06, s. 3 (1); O. Reg. 53/18, s. 2; O. Reg. 17/19, s. 2; O. Reg. 398/22, s. 2. (2) A person becomes a member of the class of eligible persons referred to in subsection (1) after the beginning of each quarter of a fiscal period only once the members of his or her household unit have spent the amount determined under sections 4, 4.1 and 4.2 on allowable expenses and the person ceases to be a member of the class at the end of the quarter. O. Reg. 374/99, s. 1 (3); O. Reg. 69/00, s. 2 (3). (3) Subject to subsection (3.1), an application under paragraph 3 of subsection (1) shall be made in the form provided by the executive officer and must include, (a) receipts for allowable expenses as required by the form; (b) information evidencing annual net income as required by the form; (b.1) information evidencing the annual amount of income from the Universal Child Care Benefit program of the Government of Canada as required by the form; (b.2) information evidencing the annual amount of taxable income withdrawn from Canadian Registered Disability Saving Plans as required by the form; and (c) completion of the consents required by the form. O. Reg. 156/05, s. 1 (2); O. Reg. 459/06, s. 3 (2); O. Reg. 556/06, s. 1; O. Reg. 94/09, s. 1. (3.1) Every application made under paragraph 3 of subsection (1) shall be deemed to be renewed every year, effective as of the first day of the fiscal period, unless, (a) the executive officer confirms that no claims for payment were submitted to the Health Network mentioned in section 23 on behalf of any member of the household unit for one fiscal period; (b) the member of the household unit that made the application on behalf of the household unit notifies the executive officer that all members of the household unit withdraw the general consent required by the application form; or (c) the member of the household unit that made the application requests that the executive officer terminate the enrolment of all members of the household unit. O. Reg. 156/05, s. 1 (2); O. Reg. 459/06, s. 3 (3-5). (3.2) If a person’s application is not renewed for one of the reasons set out in subsection (3.1), the person may reapply to be enrolled by completing the application form required by paragraph 3 of subsection (1) in accordance with subsection (3). O. Reg. 156/05, s. 1 (2). (3.3) The member of the household unit that made the application shall notify the executive officer in writing of any change in the unit’s circumstances or membership that results in a member of the household unit ceasing to be a member of the eligible class of persons, or of any other changes that may affect the calculation of the unit’s allowable expenses under section 4, 4.1 or 4.2. O. Reg. 156/05, s. 1 (2); O. Reg. 459/06, s. 3 (6). (4) Subject to subsections (6), (8) and (9), the following expenses are allowable expenses for the purposes of paragraph 2 of subsection (1): 1. The cost, including the dispensing fee, of the following products that are to be used by a member of the household unit other than a member who is an eligible person: i. A listed drug product, subject to subsection (4.1). ii. a product that is a facilitated access drug product funded under the Ontario Drug Benefit Program. iii. A listed substance. iv. A drug listed in Schedule F or G of the Food and Drugs Act (Canada) that meets the criteria set out in subsection (5). v. A nutritional product or a diabetic testing agent that is funded under the Ontario Drug Benefit Program. vi. An extemporaneous preparation that is a designated pharmaceutical product. vii. A product listed in Schedule 2. viii. A product to which the Act has been made to apply, under section 16 of the Act, in respect of the supply of the product for a member of the household unit. 2. A co-payment paid upon the purchase of a product that is referred to in paragraph 1 and is to be used by a member of the household unit who, at the time the product is purchased, is an eligible person. 3. An insurance premium paid to insure a member of the household unit against the cost of any products referred to in paragraph 1, up to a maximum premium of, i. $100 a year for a household unit of one, or ii. $200 a year for a household unit of two or more. O. Reg. 201/96, s. 3 (4); O. Reg. 336/96, s. 2 (1); O. Reg. 507/96, s. 1 (1); O. Reg. 508/96, s. 2 (2); O. Reg. 69/00, s. 2 (4-6); O. Reg. 459/06, s. 3 (7-9). (4.1) A listed drug product for which clinical criteria are specified under section 23 of the Act shall not be an allowable expense unless the product is supplied in circumstances that meet the clinical criteria. O. Reg. 336/96, s. 2 (2). (5) For the purposes of subparagraph iv of paragraph 1 of subsection (4), the cost of a drug referred to in subparagraph iv of paragraph 1 of subsection (4) is an allowable expense if, (a) the executive officer has been informed by a physician that the proper treatment of the patient requires the administration of the drug; and (b) the executive officer, on the advice of a panel of experts appointed for this purpose, recommends the use of the drug based on clinical criteria that relate to the patient’s case. O. Reg. 201/96, s. 3 (5); O. Reg. 507/96, s. 1 (2); O. Reg. 508/96, s. 2 (3); O. Reg. 459/06, s. 3 (10, 11). (6) The cost of a product referred to in paragraph 1 of subsection (4) shall not be an allowable expense if, (a) the product was not prescribed by a member of a health profession acting within the scope of his or her practice; or (b) the product is for use by a member of the household unit who, at the time the product is purchased, is not an insured person under the Health Insurance Act. O. Reg. 201/96, s. 3 (6); O. Reg. 69/00, s. 2 (7). (7) For the purposes of clause (6) (a), “health profession” means a health profession as defined in the Regulated Health Professions Act, 1991. O. Reg. 201/96, s. 3 (7). (8) If the cost of a product referred to in paragraph 1 of subsection (4) or part of the cost of that product, has been, or may be, reimbursed under the Ontario Health Insurance Plan or under an insurance plan or by an employer or a third party acting on behalf of an employer, the cost or part of that cost that may be reimbursed shall not be an allowable expense. O. Reg. 73/04, s. 1. (9) An insurance premium shall not be an allowable expense if, (a) the premium is to insure a member of the household unit who is an eligible person or who is not an insured person under the Health Insurance Act; or (b) the premium is for travel insurance for travel outside Canada. O. Reg. 201/96, s. 3 (9); O. Reg. 69/00, s. 2 (8). (10) An application submitted to the Minister before October 1, 2006 shall be deemed to have been submitted to the executive officer for the purposes of this section. O. Reg. 459/06, s. 3 (12). 4. (1) Subject to sections 4.1 and 4.2, the amount referred to in paragraphs 2 and 3 of subsection 3 (1) is equal to a quarter of, (a) with respect to a household unit whose annual net income is $100,000 or less, the amount indicated in the Table to this Regulation; and (b) with respect to a household unit whose annual net income exceeds $100,000, an amount equal to the sum of, (i) $500, and (ii) 4.5 per cent of the annual net income that exceeds $20,000, less, where applicable, (iii) $100 for a household unit of two, (iv) $150 for a household unit of three, or (v) $200 for a household unit of four or more. O. Reg. 201/96, s. 4 (1); O. Reg. 374/99, s. 2; O. Reg. 69/00, s. 3 (1). (2) Subject to subsections (4) and (5), a household unit’s annual net income shall be determined based on each member’s annual net income for his or her most recent taxation year. O. Reg. 83/98, s. 2 (1); O. Reg. 69/00, s. 3 (2). (3) For the purposes of this section, a member’s most recent taxation year is the member’s taxation year that ended before the beginning of the fiscal period in respect of which an application is made under paragraph 3 of subsection 3 (1) or renewed under subsection 3 (3.1). O. Reg. 156/05, s. 2 (1). (4) For the fiscal period that begins on April 1, 1997 and ends on July 31, 1998, the members of a household unit may elect to determine the household unit’s annual net income based on each member’s annual net income for the taxation year immediately preceding the members’ most recent taxation year. O. Reg. 83/98, s. 2 (1); O. Reg. 69/00, s. 3 (3). (5) The members of a household unit may elect to determine the household unit’s annual net income based on each member’s annual net income for the first or second taxation year immediately following the members’ most recent taxation year if the election would result in a difference of 10 per cent or more in the unit’s annual net income. O. Reg. 83/98, s. 2 (1); O. Reg. 69/00, s. 3 (4); O. Reg. 212/20, s. 1 (1). (6) In the case of an election under subsection (5), if the relevant taxation year of a member of a household unit is not complete on the day the application to be enrolled is made or the day upon which the executive officer receives the member’s written notification of his or her election, whichever is later, the member’s annual net income for that taxation year shall be determined using the sum of, (a) the member’s income from the beginning of the applicable taxation year until the day of the application or the executive officer’s receipt of the notification of election; and (b) an estimate of the member’s income from the day of the application or the executive officer’s receipt of the notification of election until the end of the applicable taxation year. O. Reg. 156/05, s. 2 (2); O. Reg. 459/06, s. 4 (1); O. Reg. 212/20, s. 1 (2). (6.1) For the purposes of subsection (6), a written notification submitted to the Minister before October 1, 2006 shall be deemed to have been submitted to the executive officer. O. Reg. 459/06, s. 4 (2). (7) An estimate under clause (6) (b) shall be determined by multiplying the number of days remaining in the member’s applicable taxation year by the member’s average daily income for the month immediately preceding the day of the application or receipt of notification. O. Reg. 156/05, s. 2 (2); O. Reg. 212/20, s. 1 (3). (8) For the fiscal period that begins on August 1, 2019 and ends on July 31, 2020, if the members of the household make an election under subsection (5) based on the members’ annual net income for the second taxation year immediately following the members’ most recent taxation year, then the household’s annual net income for the second taxation year shall only be used to determine a quarterly amount under subsection (1) for the quarter that begins on May 1, 2020 and ends on July 31, 2020. O. Reg. 212/20, s. 1 (4). (9) In this section, “annual net income” means, subject to subsection (10), the amount indicated on the applicable line of the Notice of Assessment issued under the Income Tax Act (Canada) for the relevant taxation year or, if no Notice of Assessment has been issued, the amount that would appear on that line had the Notice of Assessment been issued, in either case minus, (a) the amount of income from the Universal Child Care Benefit program of the Government of Canada that was reported or that should have been reported on the applicable line of the relevant Canadian income tax return, and (b) the amount withdrawn from Canadian Registered Disability Saving Plans that was reported or that should have been reported on the applicable line of the relevant Canadian income tax return; (“revenu annuel net”) “relevant taxation year” means, with respect to a person, the person’s most recent taxation year, or such other taxation year, as may be determined in accordance with subsections (2), (3) and (4). (“année d’imposition pertinente”) O. Reg. 83/98, s. 2 (4); O. Reg. 556/06, s. 2; O. Reg. 94/09, s. 2; O. Reg. 212/20, s. 1 (5); O. Reg. 134/25, s. 1; O. Reg. 97/26, s. 2 (1). (10) A Canada disability benefit payable under the Canada Disability Benefit Act (Canada) shall not be considered in determining annual net income. O. Reg. 97/26, s. 2 (2). 4.1 (1) The amount referred to in paragraphs 2 and 3 of subsection 3 (1) as determined under subsection 4 (1) shall be increased in accordance with subsection (2) if, (a) the amount is being determined with respect to the second, third or fourth quarter of a fiscal period; and (b) in the quarter immediately preceding the quarter in respect of which eligibility is being determined, the members of the person’s household unit spent less on allowable expenses than the amount determined under subsection 4 (1). O. Reg. 374/99, s. 3; O. Reg. 69/00, s. 4 (1); O. Reg. 156/05, s. 3. (2) The amount of the increase under subsection (1) shall be determined in accordance with the following formula: A ꞊ B – C where, A is the amount of the increase, B is the amount determined under subsection 4 (1) that the members of the person’s household unit are required to have collectively spent on allowable expenses in order to be part of the eligible class of persons referred to in subsection 3 (1), and C is the amount that the members of the person’s household unit actually spent on allowable expenses in the previous quarter of the fiscal period. O. Reg. 374/99, s. 3; O. Reg. 69/00, s. 4 (2). 4.2 (1) If the application made under paragraph 3 of subsection 3 (1) in any given fiscal period requests that eligibility begin after the beginning of the period, the amount referred to in paragraphs 2 and 3 of subsection 3 (1) that must be spent on allowable expenses in each remaining quarter of the fiscal period shall be determined in accordance with subsection (2). O. Reg. 156/05, s. 4. (2) The amount referred to in paragraphs 2 and 3 of subsection 3 (1) shall be determined in accordance with the following formula: A ꞊ B × (C/D) where, A is the amount that the members of the person’s household unit must have collectively spent on allowable expenses where subsection (1) applies, B is the amount determined under subsection 4 (1), C is the number of days from the day eligibility begins to the end of the fiscal period, and D is the total number of days in the fiscal period. O. Reg. 374/99, s. 3; O. Reg. 69/00, s. 5. 5. (1) For the purposes of sections 3 and 4, two persons are members of the same household unit if, (a) they are spouses of each other; (b) they share a residence and, (i) one is a parent, grandparent or other ancestor of the other or the legal guardian of the other, and (ii) one is dependent for support, either wholly or partly, on the other; or (c) they are each members of the same household unit with a third person under clause (a) or (b). O. Reg. 201/96, s. 5 (1); O. Reg. 69/00, s. 6 (1-3); O. Reg. 334/05, s. 2 (1). (2) Revoked: O. Reg. 69/00, s. 6 (4). (3) Revoked: O. Reg. 69/00, s. 6 (4). (4) For the purposes of this section, spouses who cease to live together because of a breakdown in their marriage or relationship are not members of the same household unit. O. Reg. 69/00, s. 6 (5); O. Reg. 334/05, s. 2 (2). (5) Despite clause (1) (b), a person is a member of the same household unit as a parent, grandparent or other ancestor or is a member of the same household unit as his or her legal guardian even if they do not share a residence so long as the person, (a) is a student; (b) is dependent for support, either wholly or partly, on the parent, grandparent, ancestor or legal guardian; and (c) elects to be part of the household unit of the parent, grandparent or other ancestor or legal guardian. O. Reg. 201/96, s. 5 (5); O. Reg. 69/00, s. 6 (6). (6) A student shall not elect to be part of the household unit of a parent, grandparent or other ancestor or of a legal guardian under clause (5) (c) if, (a) the student has elected to be part of the household unit of another parent, grandparent, ancestor or legal guardian upon whom the student is dependent for support, either wholly or partly; or (b) the person shares a residence with another parent, grandparent, ancestor or legal guardian upon whom the student is dependent for support, either wholly or partly. O. Reg. 201/96, s. 5 (6); O. Reg. 69/00, s. 6 (6). 6. An individual who is not part of the same household unit as another person pursuant to section 5 shall constitute a household unit for the purposes of sections 3 and 4. O. Reg. 69/00, s. 7. 7. Revoked: O. Reg. 459/06, s. 5. 7.1 Revoked: O. Reg. 484/05, s. 2. 7.2 Revoked: O. Reg. 459/06, s. 5. 8.-10. Revoked: O. Reg. 459/06, s. 5. Conditions for Designation of Listed Drug Products 11. (1) A strength and dosage form of a product that has been submitted for designation as an interchangeable product under the Drug Interchangeability and Dispensing Fee Act shall not be designated as a listed drug product unless the manufacturer submits the information required under section 6 of Regulation 935 of the Revised Regulations of Ontario, 1990 (General) made under that Act and the following conditions are met: 1. If the original product is a listed drug product, the drug benefit price of the product proposed to the executive officer under clause 6 (1) (d) of Regulation 935 of the Revised Regulations of Ontario, 1990 must be, i. less than or equal to 25 per cent of the drug benefit price of the original product as set out in the Formulary, A. on the date the product is first proposed for designation as a listed drug product, if no other product has been designated as interchangeable with the original product, or B. in all other cases, on the date when the first product became designated as interchangeable with the original product, or ii. if the drug benefit price of the original product has been reduced by more than 20 per cent in the 24-month period before the date on which the product is proposed for designation as a listed drug product, less than or equal to 25 per cent of the drug benefit price of the original product as set out in the Formulary immediately before the drug benefit price of the original product was first reduced. 2. If the original product was but is no longer a listed drug product, the drug benefit price of the product proposed to the executive officer under clause 6 (1) (d) of Regulation 935 of the Revised Regulations of Ontario, 1990 must be less than or equal to 25 per cent of the highest drug benefit price of the original product that was set out in the Formulary before its removal. 3. Despite paragraphs 1 and 2, for the purposes of setting the drug benefit price of an interchangeable product the executive officer may adjust the drug benefit price of the original product upon which the drug benefit price of the interchangeable product is based, having regard to the price of the original product in other provinces and territories, and the historical drug benefit price of the original product on the Formulary or as agreed to by the manufacturer and the executive officer under section 15 of this Regulation, but in doing so shall not change the actual drug benefit price of the original product on the Formulary where the original product is still listed. 4. In addition to the applicable conditions under paragraphs 1 and 2, if applicable, and if required by the executive officer, the manufacturer of the product shall enter into an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement: i. The name of the manufacturer. ii. The subject-matter of the agreement. iii. The fact of entering into or terminating the agreement. O. Reg. 459/06, s. 6; O. Reg. 559/06, s. 1 (1); O. Reg. 355/08, s. 1 (1); O. Reg. 356/08, s. 2; O. Reg. 220/10, s. 2 (1-4); O. Reg. 115/15, s. 1 (1-4); O. Reg. 123/20, s. 1. (1.1) For the purposes of paragraphs 1 and 2 of subsection (1), all references to “25 per cent” shall be read as “35 per cent” in the case of a drug product that is not a solid dosage form. O. Reg. 220/10, s. 2 (5). (2) Paragraphs 1 and 2 of subsection (1) do not apply where there is evidence satisfactory to the executive officer that the product would be the only drug product of its type that has been proposed to be designated as interchangeable with an original drug product. O. Reg. 559/06, s. 1 (2); O. Reg. 220/10, s. 2 (6). (3) Where the circumstances described in subsection (2) exist, but subject to subsections (3.1), (3.2) and (3.3), the drug benefit price of the product proposed to the executive officer must be, (a) less than or equal to 75 per cent of the drug benefit price of the original product as set out in the Formulary on the date the product is first proposed for designation as a listed drug product; (b) if the drug benefit price of the original product has been reduced by more than 20 per cent in the 24-month period before the date on which the product is proposed for designation as a listed drug product, less than or equal to 75 per cent of the drug benefit price of the original product as set out in the Formulary immediately before the drug benefit price of the original product was first reduced; or (c) if the original product was but is no longer a listed drug product, less than or equal to 75 per cent of the highest drug benefit price of the original product that was set out in the Formulary before its removal. O. Reg. 115/15, s. 1 (5). (3.1) Where the circumstances described in subsection (2) exist and there is evidence satisfactory to the executive officer that there is another product listed, sold or available for sale that is interchangeable with the original product outside Ontario but within Canada, the references to “75 per cent” in subsection (3) shall be read as “50 per cent”. O. Reg. 115/15, s. 1 (5). (3.2) The references to “75 per cent” in subsection (3) shall be read as “85 per cent” where the circumstances described in subsection (2) exist and no agreement exists respecting the payment of a volume discount or other amount by the manufacturer in respect of the original product either, (a) between the executive officer and the manufacturer of the relevant original product; or (b) between the government or other appropriate authority in any province or territory outside Ontario but within Canada and the manufacturer of the relevant original product. O. Reg. 115/15, s. 1 (5). (3.3) The exceptions set out in subsections (2), (3), (3.1) and (3.2) do not apply where there is evidence satisfactory to the executive officer that there are two or more other products listed, sold or available for sale that are interchangeable with the original product outside Ontario but within Canada, in addition to the product proposed to be designated as interchangeable with the original product in Ontario and, for greater certainty, in those circumstances, the provisions of paragraphs 1 and 2 of subsection (1) apply. O. Reg. 115/15, s. 1 (5). (4) Paragraphs 1 and 2 of subsection (1) do not apply where, after designation of the proposed product, there would be only two drug products designated as interchangeable with an original drug product. O. Reg. 115/15, s. 1 (5). (4.1) Where the circumstances described in subsection (4) exist, but subject to subsection (4.2), the drug benefit price of a product proposed to the executive officer must be, (a) less than or equal to 50 per cent of the drug benefit price of the original product as set out in the Formulary on the date the product is first proposed for designation as a listed drug product; (b) if the drug benefit price of the original product has been reduced by more than 20 per cent in the 24-month period before the date on which the product is proposed for designation as a listed drug product, less than or equal to 50 per cent of the drug benefit price of the original product as set out in the Formulary immediately before the drug benefit price of the original product was first reduced; or (c) if the original product was but is no longer a listed drug product, less than or equal to 50 per cent of the highest drug benefit price of the original product that was set out in the Formulary before its removal. O. Reg. 115/15, s. 1 (5). (4.2) The exceptions set out in subsections (4) and (4.1) do not apply where there is evidence satisfactory to the executive officer that there is another product listed, sold or available for sale that is interchangeable with the original product outside Ontario but within Canada, in addition to the two that are or are proposed to be designated as interchangeable with the original product in Ontario and, for greater certainty, in those circumstances, the provisions of paragraphs 1 and 2 of subsection (1) apply. O. Reg. 115/15, s. 1 (5). (4.3) For greater certainty, nothing in this section shall be interpreted as limiting the authority of the executive officer to maintain an agreement described in subsection 12 (7) or paragraph 7 of subsection 12.1 (1) with the manufacturer of an original product. O. Reg. 115/15, s. 1 (5). (5) Upon the application of the manufacturer, the executive officer may re-designate a drug product that was designated on the Formulary before December 31, 2007, and whose designation was removed by either of the amendments to the Formulary known as Update 8 to Edition 40, effective January 15, 2008, or Update 8A to Edition 40, effective January 17, 2008, subject to the following: 1. The submission requirements set out in subsection 12 (1) shall be deemed to have been met with respect to the product. 2. The conditions for continued listing set out in section 12.1 must be met with respect to the product. 3. The criteria established by the executive officer under section 12.2 must be met with respect to the product. O. Reg. 355/08, s. 1 (2). (6) Revoked: O. Reg. 220/10, s. 2 (8). (7) Despite paragraphs 1 and 2 of subsection (1), during the three-month period provided for in paragraph 4 of subsection (8), the drug benefit price of a product that meets the conditions set out in subsection (8) must be less than or equal to 50 per cent of the drug benefit price of the original product on the date the product is first proposed for designation as a listed drug product. O. Reg. 220/10, s. 2 (9). (8) The conditions referred to in subsection (7) are the following: 1. The product is first proposed for designation as a listed drug product on or after April 1, 2012 and has not been designated as a listed drug product at any other time. 2. The manufacturer of the product has submitted evidence satisfactory to the executive officer that the manufacturer, or another manufacturer of a product that is interchangeable with the original product, has successfully challenged the patent of the original product with the result that the manufacturer’s product can be sold in Canada earlier than if the patent had expired or if the challenge had not been brought. 3. The manufacturer has not entered into any arrangement, other than a cross-licensing agreement, with the manufacturer of the original product with respect to the product that is proposed for designation as a listed drug product, including any first-to-market arrangement or delayed-entry arrangement. 4. The manufacturer agrees that the exception set out in subsection (7) no longer applies three months after the first product of any manufacturer that is interchangeable with the original product becomes a listed drug product, at which time the drug benefit price shall be as set out in subsection (1) or any other applicable provision of this Regulation. O. Reg. 220/10, s. 2 (9). 12. (1) A strength and dosage form of a drug product shall not be designated as a listed drug product unless the manufacturer of the drug product submits to the executive officer, (a) either, (i) evidence that Health Canada has approved the product for sale in Canada and, subject to subsection (2), a copy of the product monograph approved by Health Canada, or (ii) evidence that an application has been made to Health Canada to approve the product for sale in Canada, and evidence satisfactory to a panel of experts established for the purpose that the product meets at least one of the following criteria: A. The product is a new chemical entity that is effective for the treatment of an immediately life-threatening disease or other serious disease for which it offers substantial improvements on significant outcomes, including improved efficacy, safety and tolerability and quality of life over other available drug therapies in Canada, or for which no treatment or no other effective drug therapy is currently available in Canada. B. The product is a new chemical entity that would have, if designated as a listed drug product, the effect of saving or creating efficiencies for the Government of Ontario, an average of at least $2,500,000 per year for the first three years the product is marketed in Ontario. C. The product is a new chemical entity that would have, if designated as a listed drug product, the effect of saving the Ontario Drug Benefit Program an average of at least $250,000 per year for the first three years the product is marketed in Ontario; (b) a letter authorizing the executive officer to gain access to all information with respect to the product in the possession of Health Canada, the Patented Medicine Prices Review Board established under section 91 of the Patent Act (Canada), the government of any province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health and authorizing the executive officer to disclose any information with respect to the product in the possession of the Ministry to Health Canada, the Patented Medicine Prices Review Board, the government of a province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health; (c) an estimate of the net costs to the Ontario Drug Benefit Program in a three-year period; (d) the proposed drug benefit price of the product; (e) evidence that the manufacturer is able to supply the product at the proposed drug benefit price in a quantity sufficient to meet the anticipated demand for the product; (f) certification in writing that no rebate as defined in subsection 11.5 (15) of the Act has been provided to a person listed in subsection 11.5 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada; (g) Revoked: O. Reg. 27/97, s. 1 (3). (h) clinical studies and, if available, other clinical evidence of the product’s therapeutic effectiveness or efficacy and of the product’s safety, including any information that relates to adverse drug reactions and any existing clinical studies comparing the product’s therapeutic effectiveness or efficacy and the product safety to that of other products or treatments; and (i) evidence demonstrating the benefit of the product in relation to the cost of the product and to alternative products or treatments. O. Reg. 201/96, s. 12 (1); O. Reg. 27/97, s. 1 (1-3); O. Reg. 495/00, s. 2 (1, 2); O. Reg. 338/03, s. 1; O. Reg. 645/05, s. 2; O. Reg. 459/06, s. 7 (1-4); O. Reg. 320/07, s. 2 (1); O. Reg. 436/19, s. 2 (1). (2) If Health Canada has not approved a product monograph for a drug product, the manufacturer of the drug product may, instead of submitting a copy of the product monograph as required under clause (1) (a), submit to the executive officer the following information: 1. Pharmaceutical information. 2. Information with respect to the product’s clinical pharmacology. 3. Information as to the product’s indications and clinical use. 4. A list of any contra-indications, warnings or precautions in the use of the product and of possible adverse reactions to its use. 5. A list of symptoms of an overdose of the product and information as to the treatment of an overdose. 6. Information with respect to the dosage and administration of the product. 7. Information regarding the availability of dosage forms for each strength of the product marketed in Canada. O. Reg. 201/96, s. 12 (2); O. Reg. 495/00, s. 2 (3); O. Reg. 459/06, s. 7 (5). (2.1) Clauses (1) (c), (h) and (i) do not apply to the manufacturer of a drug product if the executive officer is satisfied that the product is clinically effective and has a low risk for inappropriate utilization if designated as a listed drug product for the indication or indications in the submission and, (a) the executive officer has, since December 31, 2008 or earlier, made the Act apply in respect of the supplying of the drug in accordance with section 16 of the Act for the indication or indications in the submission; or (b) the executive officer has, since December 31, 2008 or earlier, made the Act apply in respect of the supplying of the drug in accordance with section 16 of the Act for a different indication or indications, and the Canadian Agency for Drugs and Technologies in Health has issued a positive funding recommendation in respect of the drug product for the indication or indications in the submission. O. Reg. 320/16, s. 1. (2.2) Clauses (1) (h) and (i) do not apply to the manufacturer of a biosimilar product if the executive officer is satisfied that the product is safe, therapeutically effective or efficacious, and appropriate for public funding, having regard to, (a) its approval for sale in Canada by Health Canada; (b) the availability or funding of other drug products that treat the same or similar indications, including the original biologic product; and (c) any other information available to the executive officer. O. Reg. 436/19, s. 2 (2). (2.3) Clause (1) (h) does not apply to a drug product that is not a new drug as defined in the Food and Drug Regulations made under the Food and Drugs Act (Canada) if the executive officer is satisfied that the product is safe, therapeutically effective or efficacious, and appropriate for public funding, having regard to, (a) its approval for sale in Canada by Health Canada; and (b) any other information available to the executive officer. O. Reg. 84/24, s. 1. (3) A manufacturer may satisfy the condition set out in clause (1) (h) for a strength of a drug product by submitting the clinical evidence referred to in clause (1) (h) for another strength of the same dosage form of the drug product, if the evidence is sufficient for the purposes of evaluating the therapeutic effectiveness or efficacy and the safety of both the strengths of the dosage form of the product. O. Reg. 201/96, s. 12 (3). (3.1) A manufacturer may satisfy the condition set out in clause (1) (h) for a format of a drug product by submitting the clinical evidence referred to in clause (1) (h) for another format of the drug product, if the evidence is sufficient for the purposes of evaluating the therapeutic effectiveness or efficacy and safety of both the formats of the product. O. Reg. 495/00, s. 2 (4).

(4) A manufacturer may satisfy the condition set out in clause (1) (h) for a drug product by submitting to the executive officer the clinical evidence referred to in clause (1) (h) with respect to another product and submitting evidence that satisfies the executive officer that the two products are bioequivalent. O. Reg. 201/96, s. 12 (4); O. Reg. 495/00, s. 2 (5); O. Reg. 459/06, s. 7 (6). (5) Subsection (4) does not apply if the drug product that the manufacturer seeks to have designated is the drug product of a drug for which there exists a listed drug product. O. Reg. 201/96, s. 12 (5). (5.1) Clauses (1) (h) and (i) do not apply to a generic line extension drug product if the executive officer is satisfied that the product is safe, therapeutically effective or efficacious, and appropriate for public funding, having regard to, (a) its approval for sale in Canada by Health Canada; and (b) any other information available to the executive officer. O. Reg. 436/19, s. 2 (3). (5.2) A manufacturer is exempt from complying with clauses 1 (a), (e), (h) and (i) where the executive officer is satisfied that, (a) there is a shortage of a listed drug product, or a drug to which the executive officer has made the Act apply under section 16 of the Act, with the same or similar active ingredients or therapeutic use as the drug product; and (b) the exemption is in the public interest having regard to the urgency of the situation, significant patient safety or access concerns and the cost impact to the Government of Ontario, as well as to the safety and therapeutic effectiveness or efficacy of the drug product. O. Reg. 436/19, s. 2 (4). (6) Subsection (1) does not apply to a drug product that is proposed to be designated as an interchangeable product under the Drug Interchangeability and Dispensing Fee Act. O. Reg. 201/96, s. 12 (6); O. Reg. 355/08, s. 2. (7) If required by the executive officer, the manufacturer of the product shall enter into an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement: 1. The name of the manufacturer. 2. The subject-matter of the agreement. 3. The fact of entering into or terminating the agreement. O. Reg. 459/06, s. 7 (7). (8) Despite subclause (1) (a) (ii), but subject to subsection (6), a product may not be designated as a listed drug product until evidence that satisfies subclause (1) (a) (i) is also received. O. Reg. 459/06, s. 7 (7). (8.1) It is a condition of being listed as a listed drug product that the manufacturer must not have provided a rebate as defined in subsection 11.5 (15) of the Act to a person listed in subsection 11.5 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada. O. Reg. 320/07, s. 2 (2). (9) A strength and dosage form of a drug product that contains oxycodone as the only active ingredient and that is a long-acting product that has been formulated in a solid dosage form for oral administration shall not be designated as a listed drug product unless the following conditions are met: 1. There must be evidence satisfactory to the executive officer that the drug product exhibits one or more physiochemical properties that, when compared to drugs without the property or properties, make the drug product, i. significantly more difficult to alter, break, crush, chew, dissolve or otherwise manipulate in such a way that it could be misused, abused or put to an intended use that is different than the use for which it is prescribed, or ii. significantly less effective and less likely to be misused, abused or put to an intended use that is different than the use for which it is prescribed, if the product is altered, broken, crushed, chewed, dissolved or otherwise manipulated. 2. The evidence referred to in paragraph 1 must be demonstrated by, i. in vitro testing, ii. in vivo testing, iii. another form of testing of equivalent reliability, or iv. a combination of any of the forms of testing mentioned in subparagraphs i to iii. O. Reg. 20/13, s. 2. (10) In clause (1) (a), “Government of Ontario” includes all ministries of the Government of Ontario, all programs and agencies funded by the Government of Ontario and all agencies that are established by Ontario statute or regulation but are not necessarily funded by the Government of Ontario. O. Reg. 459/06, s. 7 (7). 12.0.1 An agreement that was entered into under this section as it existed before October 1, 2006 continues in force until it expires according to its terms. O. Reg. 459/06, s. 8. 12.0.2 Revoked: O. Reg. 125/20, s. 1. Conditions to Continue to be a Designated Listed Drug Product 12.1 (1) The following conditions must be met in order for a designated listed drug product to continue to be designated as a listed drug product: 1. The manufacturer of the product shall give the executive officer notice of any change made to the product, including a formulation change, and of any change in the ownership of the manufacturer. 2. The product must be authorized for sale under the Food and Drugs Act (Canada). 3. The manufacturer of the product must continue to be able to supply the product at the drug benefit price in a quantity that is sufficient to meet the demand for the product. 4. Where the manufacturer was a party to an agreement to which this paragraph, as it read before October 1, 2006, applied, the manufacturer shall continue to be a party to that agreement until it expires according to its terms. 5. Subject to paragraphs 6.1 to 6.5, if the product has been designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act the drug benefit price of the product may not be more than the price that could be proposed to the executive officer under section 11 if a proposal was being made with respect to the drug product for the first time. 6. Revoked: O. Reg. 220/10, s. 4 (2). 6.1 Paragraph 5 does not apply with respect to a product that was designated as interchangeable with an original product on or before March 31, 2013, where there is evidence satisfactory to the executive officer that, i. the product is the only drug product of its type that is designated as interchangeable with an original drug product, and has been so designated for at least two years, and ii. removing the product’s listing would result in significant patient safety or access concerns, or significant increased costs to the Government of Ontario. 6.2 Paragraph 5 does not apply with respect to a product that has been designated as interchangeable with an original product where the manufacturer of the interchangeable product has submitted evidence satisfactory to the executive officer of substantial raw material cost increases or substantial direct manufacturing cost increases, and the executive officer is satisfied that the criteria established under section 12.2 have been met establishing that it is in the public interest that the interchangeable product be listed at a higher drug benefit price. 6.3 In the case of a drug product that was designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act before April 1, 2013, the drug benefit price of the product may not be more than the price that could have been proposed to the executive officer under section 11 as it read on March 31, 2013. 6.4 Despite paragraph 6.3, paragraph 5 applies to a drug product that was designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act before April 1, 2013 if, on or after April 1, 2018, i. another product is designated as interchangeable with the original product, or another product becomes interchangeable with the original product outside Ontario but within Canada, or ii. another product that was designated as interchangeable with the original product or another product that was interchangeable with the original product outside Ontario but within Canada is removed from the market. 6.5 When applying paragraph 5, the executive officer may adjust the drug benefit price of the original product upon which the drug benefit price of the interchangeable product is based, having regard to the price of the original product in other provinces and territories and to the historical drug benefit price of the original product on the Formulary or a price that was agreed to by the executive officer and the manufacturer under section 15. However, in doing so, the executive officer shall not change the actual drug benefit price of the original product on the Formulary. 6.6 Revoked: O. Reg. 436/19, s. 3 (2). 6.7 Revoked: O. Reg. 436/19, s. 3 (2). 6.8 Revoked: O. Reg. 436/19, s. 3 (2). 7. If required by the executive officer, the manufacturer of the product shall enter into and remain a party to an agreement with the executive officer that specifies any volume discount or other amount that may be payable by the manufacturer to the Minister of Finance, and shall agree that the executive officer may make public the following information, and that information only, with respect to the agreement: i. The name of the manufacturer. ii. The subject-matter of the agreement. iii. The fact of entering into or terminating the agreement. 8. If required by the executive officer, the manufacturer of a product that has been designated as interchangeable under the Drug Interchangeability and Dispensing Fee Act shall inform the executive officer of the price that the manufacturer receives for the product, net of the value of any ordinary commercial terms. O. Reg. 459/06, s. 9; O. Reg. 559/06, s. 2 (1, 2); O. Reg. 320/07, s. 3 (1-4); O. Reg. 355/08, s. 3 (1-3); O. Reg. 220/10, s. 4 (1-4); O. Reg. 115/15, s. 2 (1-3); O. Reg. 436/19, s. 3 (1, 2). (2) For greater certainty, the conditions set out in subsection (1) apply whether the designation as a listed drug product or as an interchangeable product under the Drug Interchangeability and Dispensing Fee Act took place before, on or after July 1, 2010. O. Reg. 459/06, s. 9; O. Reg. 220/10, s. 4 (5). (3) Where the circumstances described in paragraph 6.1 or 6.2 of subsection (1) exist, the executive officer may, in the executive officer’s sole discretion, negotiate an agreement with the manufacturer for any drug benefit price, but, (a) in no case may the interchangeable product be priced higher than the original product, unless, (i) the manufacturer has submitted detailed information to the executive officer demonstrating why the product should be priced higher than the original product, and (ii) the executive officer considers such a price to be in the public interest, having regard to the matters set out in subsection 22 (2) of the Act and to anything else the executive officer considers relevant; and (b) in respect of a product for which the only applicable circumstances are those set out in paragraph 6.1 of subsection (1), if the circumstance set out in subparagraph 6.1 i of subsection (1) no longer applies, the drug benefit price of the product shall revert to a price that is less than or equal to 25 per cent of the drug benefit price of the original product as set out in the Formulary on the date that the product was first proposed for designation as a listed drug product. O. Reg. 220/10, s. 4 (6). (4)-(7) Revoked: O. Reg. 436/19, s. 3 (3). (8) For the purposes of this section, in determining the price of an original product as of the applicable date, the executive officer may make the adjustments set out in subsection (9) in determining the price of the original product in the case of an interchangeable product, where, (a) the original product has not been a listed drug product or has not been sold in Ontario for at least 10 years; and (b) the interchangeable product is one of no more than two listed drug products that are designated as interchangeable with the original product. O. Reg. 115/15, s. 2 (4). (9) The adjustments mentioned in subsection (8) are as follows: 1. Determine the highest drug benefit price at which the original product was listed. 2. Commencing in the year in which the original product ceased to be listed or sold in Ontario, add an amount to reflect the average increase in consumer prices shown in Statistics Canada’s Consumer Price Index for Ontario (All Items) for each succeeding year to, i. a maximum of 10 years, or ii. a number of years determined by the executive officer that exceeds 10, where the executive officer is satisfied that it is in the public interest to make such a determination. O. Reg. 115/15, s. 2 (4). (10) Paragraphs 2 and 3 of subsection (1) do not apply with respect to a drug product or drug that is the subject of an exemption under subsection 12 (5.2). O. Reg. 436/19, s. 3 (4). Establishing Criteria 12.2 Pursuant to subsection 1.1 (9) of the Act, it is provided that, (a) the executive officer has the power to establish criteria that must be met for the purposes of paragraph 6.2 of subsection 12.1 (1) in order to establish that it is in the public interest to list a drug product at a higher drug benefit price; and (b) the executive officer shall publish those criteria on the Ministry website. O. Reg. 355/08, s. 4. Amounts Paid by Executive Officer 13. (1) For the purposes of paragraph 2 of subsection 6 (1) of the Act, the drug benefit price of a listed drug product is the price set out opposite the listed drug product in the Formulary. O. Reg. 201/96, s. 13 (1); O. Reg. 459/06, s. 10 (1). (2) For the purposes of paragraph 3 of subsection 6 (1) of the Act, the mark-up on the drug benefit price of a listed drug product is, (a) 8.5 per cent of the drug benefit price, if the total drug cost of the product when supplied is less than $100; (b) 8 per cent of the drug benefit price, if the total drug cost of the product when supplied is $100 or more but less than $500; (c) 7 per cent of the drug benefit price, if the total drug cost of the product when supplied is $500 or more but less than $1,000; (d) 6 per cent of the drug benefit price, if the total drug cost of the product when supplied is $1,000 or more but less than $2,000; (e) 5.5 per cent of the drug benefit price, if the total drug cost of the product when supplied is $2,000 or more but less than $4,000; and (f) 5 per cent of the drug benefit price, if the total drug cost of the product when supplied is $4,000 or more. O. Reg. 157/24, s. 1. (3) In subsection (2), “total drug cost” means the amount that is calculated by multiplying the drug benefit price of the drug product supplied by the quantity of the drug product supplied. O. Reg. 157/24, s. 1. (3.1) Revoked: O. Reg. 157/24, s. 1. (4) For the purpose of subclause 6 (2) (c) (i) of the Act, the dispensing fee for a listed drug product is the fee set out in Column 2 of the Table to this subsection opposite the description of the pharmacy in which the listed drug product is dispensed. O. Reg. 201/96, s. 13 (4); O. Reg. 431/19, s. 1 (1). Table Item Column 1 Description Of Pharmacy Column 2 Dispensing Fee 1. Pharmacy other than a pharmacy provided for in item numbers 2, 3 or 4 $8.83 2. Pharmacy located in a postal code with the second figure of 0 or with a score on the Ministry of Health and Long-Term Care’s Rurality Index for Ontario of more than 40, and one of the following conditions is met: 1. There is no other pharmacy within 5 kilometres. 2. The nearest other pharmacy is no more than 5 kilometres away and is the only other pharmacy in a 5 kilometre radius. 3. The nearest other pharmacy is at least 5 kilometres away but no more than 10 kilometres $9.93 3. Pharmacy located in a postal code with the second figure of 0 or with a score on the Ministry of Health and Long-Term Care’s Rurality Index for Ontario of more than 40, and the nearest other pharmacy is at least 10 kilometres away but no more than 25 kilometres $12.14 4. Pharmacy located in a postal code with the second figure of 0 or with a score on the Ministry of Health and Long-Term Care’s Rurality Index for Ontario of more than 40, and the nearest other pharmacy is at least 25 kilometres away $13.25 O. Reg. 220/10, s. 5; O. Reg. 284/15, s. 1 (2). (5) Despite subsection (4), for the purposes of subclause 6 (2) (c) (i) of the Act, the dispensing fee for a listed drug product that is dispensed from one of the following locations or systems shall be the amount set out in item 1 of the Table to that subsection, without regard to item 2, 3 or 4. 1. A remote dispensing location within the meaning of the Drug and Pharmacies Regulation Act. 2. An automated pharmacy system that is operated in or by a public hospital within the meaning of the Public Hospitals Act, or another dispensing system operated in or by such a hospital that is substantially similar to a remote dispensing location mentioned in paragraph 1. O. Reg. 228/11, s. 2; O. Reg. 284/15, s. 1 (3); O. Reg. 431/19, s. 1 (2). (6) Revoked: O. Reg. 431/19, s. 1 (3). 14. (1) For the purposes of subsections 4 (5), 6 (3) and (4) of the Act, the acquisition cost of a listed drug product supplied for an eligible person is the amount calculated by, (a) determining, in accordance with subsection (2), the amount payable by the operator of the pharmacy to the manufacturer or wholesaler of the listed drug product for a shipment or order of the product, a portion of which was supplied for the eligible person; (b) dividing the amount determined under clause (a) by the number of units of the listed drug product purchased from the manufacturer or wholesaler; and (c) multiplying the unit cost determined under clause (b) by the number of units of the product or drug supplied for the eligible person. O. Reg. 201/96, s. 14 (1); O. Reg. 459/06, s. 11 (1). (2) The amount payable referred to in clause (1) (a) shall be the full amount payable for a shipment or order of a listed drug product less any amount charged for shipping and handling of the listed drug product. O. Reg. 459/06, s. 11 (2). (3) The operator of a pharmacy may submit a claim for payment in accordance with subsection 6 (3) of the Act where the executive officer is satisfied that, (a) Revoked: O. Reg. 559/06, s. 3 (2). (b) the operator of a pharmacy is unable to acquire an interchangeable drug product and must dispense the original product or an interchangeable product with a higher drug benefit price. O. Reg. 559/06, s. 3. 15. (1) The drug benefit price of a drug for which there is not a listed drug product, and to which the executive officer has made the Act apply under section 16 of the Act, shall be the price agreed to by the manufacturer and the executive officer. O. Reg. 459/06, s. 12. (2) The amount that the executive officer shall pay under subsection (1) shall be the amount as determined in section 6 of the Act and, if applicable, includes a compounding fee determined by the executive officer under subsection 17 (2) of the Act. O. Reg. 459/06, s. 12. (3) The executive officer shall publish the price agreed to under subsection (1) on the Ministry’s website. O. Reg. 459/06, s. 12. 16. Revoked: O. Reg. 64/23, s. 1 (4). 17. (1) The amount the executive officer shall pay a physician under subsection 5 (3) of the Act is the amount calculated by adding the amounts determined under paragraphs 1, 2 and 3 and subtracting from that total the maximum co-payment that may be charged in respect of the supplying of a listed drug product for an eligible person: 1. The dispensing fee determined under subsection (2). 2. The drug benefit price set out opposite the listed drug product in the Formulary but, if there are other listed drug products that are interchangeable with the drug product, the drug benefit price shall be deemed to be the lowest of the drug benefit prices for the drug product and the listed drug products that are interchangeable with it. 3. A mark-up equal to, i. 8.5 per cent of the drug benefit price, if the total drug cost of the product supplied is less than $100, ii. 8 per cent of the drug benefit price, if the total drug cost of the product supplied is $100 or more but less than $500, iii. 7 per cent of the drug benefit price, if the total drug cost of the product supplied is $500 or more but less than $1,000, iv. 6 per cent of the drug benefit price, if the total drug cost of the product supplied is $1,000 or more but less than $2,000, v. 5.5 per cent of the drug benefit price, if the total drug cost of the product supplied is $2,000 or more but less than $4,000, and vi. 5 per cent of the drug benefit price, if the total drug cost of the product supplied is $4,000 or more. O. Reg. 459/06, s. 13; O. Reg. 284/15, s. 2 (1); O. Reg. 157/24, s. 2. (1.1) In paragraph 3 of subsection (1), “total drug cost” means the amount that is calculated by multiplying the drug benefit price of the drug product supplied by the quantity of the drug product supplied. O. Reg. 284/15, s. 2 (2). (2) The dispensing fee referred to in paragraph 1 of subsection (1) shall be, (a) in the case of a physician whose office is within 20 kilometres of an accredited pharmacy, $4.28; and (b) in any other case, $5.10. O. Reg. 459/06, s. 13 (1). (3) Subsections 6 (3), (4) and (5) of the Act and sections 14 and 15 of this Regulation apply with necessary modifications with respect to amounts payable by the executive officer to physicians under subsection 5 (3) of the Act. O. Reg. 459/06, s. 13 (1). Limits on Amounts Paid by Executive Officer 18. (1) Revoked: O. Reg. 134/18, s. 1 (1). (2) If an eligible person will be leaving Ontario for a period of at least 100 consecutive days within six months after the day a listed drug product is supplied for the person, the executive officer is only required to pay under the Act for the quantity of the product supplied for the person at one time that is sufficient for a 100-day course of treatment. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (2). (3) The executive officer is only required to pay under the Act for the quantity of a listed drug product supplied for an eligible person, other than a person mentioned in subsection (2), at one time that is sufficient for a 30-day course of treatment if the product supplied is a product other than insulin and if the product supplied has not been supplied for the person within the previous 12-month period. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (3); O. Reg. 134/18, s. 1 (2). (4) Despite subsection (3), the executive officer is required to pay for the quantity of a listed drug product described in that subsection that is sufficient for a 100-day course of treatment if, in the opinion of the person dispensing the product, the person will not be able to obtain a further supply of the product at the end of a 30-day course of treatment. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (4). (5) The executive officer is only required to pay under the Act for the quantity of a listed drug product supplied for an eligible person, other than a person mentioned in subsection (2), at one time that is sufficient for a 100-day course of treatment if the listed drug product supplied is a product other than one mentioned in subsection (3). O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (5); O. Reg. 134/18, s. 1 (3). (6) The following rule applies for the purposes of subsections (2), (4) and (5): 1. If a listed drug product is supplied for a person who is part of the eligible class of persons designated under section 3 and if, by supplying a 100-day course of treatment of the product, the last day of the course of treatment would be more than 30 days after the end of the period for which the person is eligible, the executive officer is only required under the Act to pay for the quantity of the listed drug product sufficient for a course of treatment that ends 30 days after the end of the period for which the person is eligible. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (6). (7) It is a condition for payment of a dispensing fee that the dispenser supply at one time to an eligible person the lesser of, (a) the maximum quantity of a listed drug product for which the executive officer is required to pay under subsections (2) to (6); or (b) the maximum quantity of the listed drug product that the dispenser is authorized to supply at one time. O. Reg. 264/08, s. 1 (1); O. Reg. 284/15, s. 3 (1); O. Reg. 134/18, s. 1 (4). (8) The condition for payment of a dispensing fee set out in subsection (7) does not apply if, (a) the listed drug product is a product or belongs to a class of drug product that is specified by the executive officer and published on the Ministry website and the dispenser has determined that the quantity supplied should be less than the amount required under subsection (7) because, in the dispenser’s professional opinion, (i) the safety of the eligible person is a concern, or (ii) there is a risk of abuse or diversion if the drug product is supplied to the eligible person; (b) the eligible person is a resident of a residential facility, other than a long-term care home under the Fixing Long-Term Care Act, 2021, that is funded by the Government of Ontario and is designated by the executive officer in a designation published on the Ministry website; or (c) the dispenser has determined that the quantity supplied should be less than the amount required under subsection (7) because, (i) in the dispenser’s professional opinion, the eligible person is incapable of managing his or her medication as a result of physical, cognitive or sensory impairment, and (ii) the eligible person or the person presenting the prescription agrees that the quantity supplied should be less than the amount required under subsection (7). O. Reg. 264/08, s. 1 (1, 2); O. Reg. 284/15, s. 3 (2); O. Reg. 431/19, s. 3 (1); O. Reg. 309/22, s. 2 (1). (8.1) Where the dispenser has made a determination under clause (8) (a), (a) the dispenser shall make a written record of the reasons for his or her opinion; (b) the dispenser shall notify the prescriber in writing about the determination and retain a copy of the notification; and (c) the dispenser shall provide copies of the written record described in clause (a) and the written notification described in clause (b) to the executive officer on request. O. Reg. 284/15, s. 3 (3). (9) Where the dispenser has made a determination under clause (8) (c), (a) the dispenser shall make a written record of the reasons for his or her opinion under subclause (8) (c) (i); (b) the dispenser shall obtain in writing the agreement required under subclause (8) (c) (ii) of the eligible person or of the person presenting the prescription; (c) the dispenser shall notify the prescriber in writing about the determination and retain a copy of the notification; and (d) the dispenser shall provide copies of the written record, agreement and notification described in clauses (a), (b) and (c) to the executive officer on request. O. Reg. 284/15, s. 3 (4). (10) The executive officer shall not pay more than two dispensing fees for the supply of a listed drug product in a 28-day period even if the prescription specifies intervals such that the listed drug product is to be dispensed in more than two intervals in the 28-day period, unless, (a) the listed drug product is dispensed in the circumstances described in clause (8) (a) or (b); or (b) the listed drug product is a product or belongs to a class of drug product that is specified by the executive officer and published on the Ministry website. O. Reg. 284/15, s. 3 (4); O. Reg. 93/16, s. 1. (11) Pursuant to subsection 1.1 (9) of the Act, it is provided that the executive officer has the power, (a) to specify a listed drug product or class of listed drug product for the purposes of clauses (8) (a) and (10) (b); and (b) to designate a residential facility for the purposes of clauses (8) (b) and (11.1) (a). O. Reg. 284/15, s. 3 (4); O. Reg. 431/19, s. 3 (2). (11.1) Despite subsection (10), where the listed drug product is a product or belongs to a class of drug product that has been specified by the executive officer and published on the Ministry’s website, the executive officer shall not pay more than five dispensing fees in a year for the supply of the listed drug product, even if the intervals specified in the prescription provide for the listed drug product to be dispensed more than five times in the year, unless the listed drug product, (a) is supplied to an eligible person who is a resident of a residential facility, other than a long-term care home under the Fixing Long-Term Care Act, 2021, that is funded by the Government of Ontario and is designated by the executive officer in a designation published on the Ministry website; (b) Revoked: O. Reg. 134/18, s. 1 (5). (c) is supplied to an eligible person who is on a complex medication regime that has been specified by the executive officer and published on the Ministry’s website and who requires more frequent dispensing of the listed drug product to assist with the proper administration of the medication regime; (d) is supplied in accordance with clause 18 (8) (c) and subsection 18 (9) of this Regulation; or (e) is an extemporaneous preparation. O. Reg. 284/15, s. 3 (4); O. Reg. 134/18, s. 1 (5); O. Reg. 431/19, s. 3 (3); O. Reg. 309/22, s. 2 (2). (11.2) For the purposes of subsection (11.1), “year” is a period of 365 days, with the first year commencing on the day the first claim for payment for the relevant listed drug product is submitted by the dispenser to the executive officer following the coming into force of subsection (11.1), and all subsequent years commencing on the day the first claim for payment for the relevant listed drug product is submitted by the dispenser to the executive officer following the end of the previous year. O. Reg. 284/15, s. 3 (4). (11.3) Pursuant to subsection 1.1 (9) of the Act, it is provided that the executive officer has the power, (a) to specify a listed drug product or class of listed drug product for the purposes of subsection (11.1); and (b) to specify a complex medication regime for the purposes of clause (11.1) (c). O. Reg. 284/15, s. 3 (4). (12) If the executive officer specifies a listed drug product or class of listed drug product under clause (11) (a) or designates a residential facility under clause (11) (b), he or she shall publish the specification or designation on the Ministry website. O. Reg. 264/08, s. 1 (1). 19. (1) For the purposes of subsections 4 (6) and 6 (5) of the Act, the executive officer shall not pay the amount determined under subsection 4 (5) of the Act in respect of a prescription that contains a direction that there be no substitutions unless the following conditions are met: 1. In the case of a written prescription, the direction is made by the prescriber writing “no sub” or “no substitutions” on the prescription. 2. The eligible person for whom the listed drug product is supplied has previously been administered and experienced an adverse reaction to, i. another drug product that is interchangeable with the drug product supplied, in the case where only one product has been designated as interchangeable with the drug product supplied and is generally available for sale in Ontario, or ii. two drug products that are interchangeable with the drug product supplied, in the case where two or more products have been designated as interchangeable with the drug product supplied and are generally available for sale in Ontario. 3. The adverse reaction described in paragraph 2 is documented for each applicable interchangeable product as follows: i. In the case of a written prescription, the prescription is accompanied by an adverse drug reaction reporting form completed and signed by the prescriber in which the interchangeable product that caused the adverse reaction is identified. ii. In the case of a verbal prescription, the prescriber satisfies the operator of the pharmacy or the dispensing physician that an adverse drug reaction reporting form in which the interchangeable product that caused the adverse reaction is identified has been completed and signed by the prescriber and will be delivered to the operator of the pharmacy or the dispensing physician forthwith. O. Reg. 284/15, s. 4. (2) In paragraph 3 of subsection (1), “adverse drug reaction reporting form” means the Health Canada adverse drug reaction reporting form available from Health Canada or from the Ministry. O. Reg. 284/15, s. 4. (3) This section, as it existed immediately before October 1, 2015, continues to apply to prescriptions authorized by a prescriber before that day, including any renewals or extensions of those prescriptions that take the form of new prescriptions. O. Reg. 284/15, s. 4. 20. (1) The amount payable by the executive officer to the operator of a pharmacy in respect of methadone provided to an eligible person is an amount determined by an agreement between the operator and the executive officer. O. Reg. 459/06, s. 16. (2) The amount payable by the executive officer to the operator of a pharmacy in respect of a listed drug product provided to an eligible person described in paragraph 5 of subsection 2 (1) is an amount determined by an agreement between the operator and the executive officer. O. Reg. 431/19, s. 4. Co-payment 20.1 (1) For the purposes of subsection 6 (1) of the Act and subsection 17 (1) of this Regulation, the maximum co-payment that the operator of a pharmacy or a physician may charge a person in respect of supplying a listed drug product for an eligible person is $2 or the operator’s usual and customary dispensing fee, whichever is less, unless a different co-payment is provided for under section 20.2. O. Reg. 284/15, s. 5; O. Reg. 347/17, s. 3 (1). (1.1) Despite subsection (1), the maximum co-payment that the operator of a pharmacy or a physician may charge a person in respect of supplying a listed drug product for an eligible person who is under 25 years of age is $0, unless the person is an eligible person described in subsection 3 (1). O. Reg. 17/19, s. 3. (2) The maximum co-payments described in subsection (1) and paragraph 3 of subsection 20.2 (4) may only be charged by an operator of a pharmacy or a physician if the executive officer is required to pay the operator of the pharmacy or the physician a dispensing fee under the Act and this Regulation. O. Reg. 284/15, s. 5; O. Reg. 97/26, s. 3. (3) Revoked: O. Reg. 211/20, s. 2 (2). 20.2 (1) If a listed drug product is supplied for an eligible person described in subsection (3), the maximum co-payment that the operator of a pharmacy may charge in respect of the supply of the drug product for that eligible person shall be determined in accordance with this section. O. Reg. 97/26, s. 4 (3). (2) In this section, “allowable drug costs” means the sum of any amount spent on co-payments in respect of listed drug products, and in respect of listed substances, that are supplied for an eligible person in the current fiscal period; (“coûts des médicaments autorisés”) “deductible amount” means an amount determined in accordance with subsection (5) or (6), as applicable; (“franchise”) “fiscal period” means the period of July 15, 1996 to March 31, 1997, the period of April 1, 1997 to July 31, 1998 and each succeeding 12-month period that commences on August 1 of each year and ends on July 31 of the following year. (“exercice”) O. Reg. 97/26, s. 4 (3). (3) Subject to section 20.3, this section applies with respect to eligible persons referred to in paragraph 4 of subsection 2 (1) who are not part of any other class of eligible persons under the Act. O. Reg. 97/26, s. 4 (3). (4) The maximum co-payment that may be charged in respect of the supply of a listed drug product for an eligible person under this section during a fiscal period shall be determined in accordance with the following rules: 1. Until the eligible person’s allowable drug costs for the fiscal period reach the deductible amount, the maximum co-payment that may be charged shall be the amount equal to the full amount otherwise payable by the executive officer under section 6 of the Act, or section 17 of this Regulation, as the case may be, in respect of the supply of the drug product less, i. if the drug product is supplied in a pharmacy operated in a hospital approved as a public hospital under the Public Hospitals Act, $6.00, ii. in all other cases, the amount, if any, by which the dispensing fee exceeds $6.11. 2. Despite paragraph 1, if charging the maximum co-payment permitted under that paragraph would result in the eligible person’s allowable drug costs for the current fiscal period exceeding the deductible amount, the maximum co-payment that may be charged shall be the difference between the deductible amount and the amount of the eligible person’s allowable drug costs paid so far in the current fiscal period. 3. On or after the day the eligible person’s allowable drug costs for the fiscal period reach or exceed the deductible amount, the maximum co-payment that may be charged for the remainder of the fiscal period shall be, i. if the drug product is supplied in a pharmacy operated in a hospital under the Public Hospitals Act, $2.83, ii. if the drug product is supplied by a physician whose office is within 20 kilometres of an accredited pharmacy, $4.28, iii. if the drug product is supplied by a physician whose office is more than 20 kilometres from an accredited pharmacy, $5.10, iv. in all other cases, the lesser of $6.11 or the amount the operator of the pharmacy that supplied the drug product sets as its dispensing fee under subsection 6 (1) of the Drug Interchangeability and Dispensing Fee Act. O. Reg. 97/26, s. 4 (3). (5) For the purposes of subsection (4), the deductible amount used to determine the maximum co-payment that may be charged for the supply of a listed drug product for an eligible person during any fiscal period is $100. O. Reg. 97/26, s. 4 (3). (6) Despite subsection (5), if a person becomes eligible under the Act during a fiscal period, the deductible amount used under subsection (4) to determine the maximum co-payment that may be charged during the fiscal period for the supply of a listed drug product for that eligible person is set out in Column 2 of Table 1 to this subsection opposite the period during which the person becomes eligible set out in Column 1 of Table 1. O. Reg. 97/26, s. 4 (3). TABLE 1 Deductible Amounts When Person Becomes Eligible During Fiscal Period Item Column 1 Month in which person becomes eligible Column 2 Deductible Amount 1. On August 1 $100.00 2. On or after August 2 but before September 2 91.67 3. On or after September 2 but before October 2 83.33 4. On or after October 2 but before November 2 75.00 5. On or after November 2 but before December 2 66.67 6. On or after December 2 but before January 2 58.33 7. On or after January 2 but before February 2 50.00 8. On or after February 2 but before March 2 41.67 9. On or after March 2 but before April 2 33.33 10. On or after April 2 but before May 2 25.00 11. On or after May 2 but before June 2 16.67 12. On or after June 2 but before August 1 8.33 O. Reg. 97/26, s. 4 (3). 20.3 (1) In this section, “fiscal period” has the same meaning as in section 20.2; (“exercice”) “relevant taxation year” means, with respect to a person, the person’s most recent taxation year, or such other taxation year, as may be determined in accordance with section 20.4. (“année d’imposition pertinente”) O. Reg. 97/26, s. 5. (2) Section 20.2 does not apply and, instead, the maximum co-payment that may be charged in respect of the supply of a listed drug product for an eligible person during a fiscal period is the amount referred to in subsection 20.1 (1) if the eligible person, (a) applied to the Ministry, in the current fiscal period or in any previous fiscal period, for relief from the section 20.2 maximum co-payment; and (b) meets the criteria set out in any of the paragraphs of subsection (3). O. Reg. 97/26, s. 5. (3) In order to qualify for relief from the section 20.2 maximum co-payment, the eligible person must meet the criteria in one of the following paragraphs: 1. The eligible person must, i. not have a spouse, and ii. at the time of their application, have had an individual annual net income that was equal to or less than the applicable individual annual net income threshold established in section 20.5. 2. The eligible person must, i. have a spouse, ii. not meet either of the conditions set out in subparagraph 3 i, and iii. at the time of their application, have had, along with their spouse, a combined annual net income that was equal to or less than the applicable combined annual net income threshold established in section 20.5. 3. The eligible person must, i. either, A. be married but no longer live in a conjugal relationship with their spouse, or B. have a spouse who is a person mentioned in paragraph 2, 5 or 6 of subsection 2 (1), and ii. at the time of their application, have had an individual annual net income that was equal to or less than the applicable individual annual net income threshold established in section 20.5. O. Reg. 97/26, s. 5. (4) Despite subsection (2), the eligible person’s relief from the section 20.2 maximum co-payment terminates at the end of the fiscal period to which their application relates if the eligible person meets the criteria set out in subsection (3) at the time of their application, based on income reported in their application, but the Ministry, (a) is not able to verify that income with the Canada Revenue Agency; and (b) does not receive a Notice of Assessment issued under the Income Tax Act (Canada) for the eligible person or, if applicable, their spouse. O. Reg. 97/26, s. 5. (5) For greater certainty, the denial of an application under this section or the termination of an eligible person’s relief from the section 20.2 maximum co-payment does not prevent an eligible person from re-applying for that relief in respect of another fiscal period. O. Reg. 97/26, s. 5. (6) If, after an application is made in accordance with this section, the eligible person’s relationship status changes, or their spouse experiences a life change, such that the eligible person would no longer meet the criteria set out in subparagraph 1 i, 2 i or ii or 3 i of subsection (3), as the case may be, that they met at the time of their application, the eligible person must notify the Ministry of the change and, if requested to do so, provide such information as the Ministry may require to assess whether the eligible person currently meets the criteria set out in subsection (3). O. Reg. 97/26, s. 5. (7) An eligible person must provide the notice and information required by subsection (6) in a timely manner as a condition of continuing to maintain their relief from the section 20.2 maximum co-payment. O. Reg. 97/26, s. 5. (8) If the Ministry determines, whether due to a notice provided in accordance with subsection (6) or otherwise, that an eligible person’s relationship status has changed, or that their spouse has experienced a life change, such that the eligible person would no longer meet the criteria set out in subparagraph 1 i, 2 i or ii or 3 i of subsection (3), as the case may be, that they met at the time of their application, the Ministry shall reassess the eligible person’s application as if they had submitted a new application under this section. O. Reg. 97/26, s. 5. 20.4 (1) This section sets out the rules for determining individual and combined annual net incomes for the purposes of subsection 20.3 (3). O. Reg. 97/26, s. 5. (2) In this section, “annual net income” means, subject to subsection (3), the amount indicated on the applicable line of the Notice of Assessment issued under the Income Tax Act (Canada) for the relevant taxation year or, if no Notice of Assessment has been issued, the amount that would appear on that line had the Notice of Assessment been issued, in either case minus, (a) the amount of income from the Universal Child Care Benefit program of the Government of Canada that was reported or that should have been reported on the applicable line of the relevant Canadian income tax return, and (b) the amount withdrawn from Canadian Registered Disability Saving Plans that was reported or that should have been reported on the applicable line of the relevant Canadian income tax return; (“revenu annuel net”) “fiscal period” and “relevant taxation year” have the same meaning as in section 20.3. (“exercice”, “année d’imposition pertinente”) O. Reg. 97/26, s. 5. (3) A Canada disability benefit payable under the Canada Disability Benefit Act (Canada) shall not be considered in determining annual net income. O. Reg. 97/26, s. 5. (4) The individual annual net income for an eligible person referred to in paragraph 1 or 3 of subsection 20.3 (3) shall be the annual net income for their most recent taxation year that ended before the beginning of the fiscal period in respect of which their application is made. O. Reg. 97/26, s. 5. (5) The combined annual net income for an eligible person and their spouse referred to in paragraph 2 of subsection 20.3 (3) shall be determined based on each person’s annual net income for their most recent taxation year that ended before the beginning of the fiscal period in respect of which their application is made. O. Reg. 97/26, s. 5. (6) Despite subsections (4) and (5), an eligible person may elect, for the fiscal period that began on April 1, 1997 and ended on July 31, 1998, to have their annual net income and, if applicable, the annual net income of their spouse, be their annual net income for the 1995 taxation year. O. Reg. 97/26, s. 5. (7) Despite subsection (4), an eligible person who meets the criteria in paragraph 1 or 3 of subsection 20.3 (3) may elect to have their individual annual net income determined based on their annual net income for the taxation year immediately following the most recent taxation year that ended before the beginning of the fiscal period in respect of which their application is made if the election would result in a difference of 10 per cent or more in their individual annual net income. O. Reg. 97/26, s. 5. (8) Despite subsection (5), an eligible person who meets the criteria in paragraph 2 of subsection 20.3 (3) may elect to have their combined annual net income with their spouse determined based on each person’s annual net income for the taxation year immediately following the most recent taxation year that ended before the beginning of the fiscal period in respect of which their application is made if the election would result in a difference of 10 per cent or more in their combined annual net income. O. Reg. 97/26, s. 5. (9) Subsections 4 (6) and (7) apply to the determination of the annual net income in the case of an election under subsection (7) or (8) of this section. O. Reg. 97/26, s. 5. 20.5 (1) This section sets out the rules for determining the annual net income thresholds for the purposes of subsection 20.3 (3). O. Reg. 97/26, s. 5. (2) For applications that relate to a fiscal period that begins before August 1, 2024, the income thresholds that apply to an eligible person’s application for relief from the section 20.2 maximum co-payment are the applicable individual or combined thresholds that were set out in this Regulation on the first day of the fiscal period to which the application relates. O. Reg. 97/26, s. 5. (3) For applications that relate to a fiscal period that begins on August 1, 2024 or on August 1, 2025, the income thresholds that apply to an eligible person’s application for relief from the section 20.2 maximum co-payment are the following: 1. The individual annual net income threshold is $25,000. 2. The combined annual net income threshold is $41,500. O. Reg. 97/26, s. 5.

(4) For applications that relate to a fiscal period that begins on or after August 1, 2026, the income thresholds that apply to an eligible person’s application for relief from the section 20.2 maximum co-payment shall be adjusted by taking the amount calculated using the following formula and rounding it up to the next highest 10 dollars: A + {A × [(B/C) – 1]} in which, “A” is the income threshold for the preceding fiscal period, “B” is the average Consumer Price Index for Ontario (All Items), as published by Statistics Canada under the authority of the Statistics Act (Canada), for the 12-month period that ended on December 31 of the previous year, and “C” is, subject to subsection (6), the average Consumer Price Index for Ontario (All Items), as published by Statistics Canada under the authority of the Statistics Act (Canada), for the 12-month period preceding the 12-month period mentioned in the description of “B”. O. Reg. 97/26, s. 5. (5) Despite subsection (4), if the adjustment under that subsection would result in a lower threshold for a fiscal period than in the previous fiscal period, the income threshold for the fiscal period shall not be adjusted and shall instead remain at the same amount as for the previous fiscal period. O. Reg. 97/26, s. 5. (6) If no adjustment to the income threshold occurs for a fiscal period due to the application of subsection (5), then, for the first subsequent fiscal period for which an adjustment is to occur, the value of “C” in subsection (4) shall instead be equal to the value of “B” that was used for the most recent prior increase to the income thresholds under subsection (4). O. Reg. 97/26, s. 5. (7) The Ministry shall publish the threshold amounts determined in accordance with subsection (4) or (5), as applicable, on a website of the Government of Ontario. O. Reg. 97/26, s. 5. Amount Charged to Person Other Than Executive Officer 21. (1) In addition to any amounts authorized in the Act, the operator of a pharmacy who supplies a listed drug product for an eligible person may charge, or accept payment from, a person other than the executive officer in accordance with this section. O. Reg. 201/96, s. 21 (1); O. Reg. 459/06, s. 19 (1). (2) If the quantity of a listed drug product supplied at one time for an eligible person exceeds the maximum quantity for which the executive officer may pay under section 18, the operator of the pharmacy that supplied the product may charge a person other than the executive officer an amount in respect of the additional quantity supplied. O. Reg. 201/96, s. 21 (2); O. Reg. 459/06, s. 19 (2). (3) The operator of a pharmacy shall not charge an amount under subsection (2) unless, (a) the operator explains to the person who purchases the listed drug product the reason for the charge; and (b) the operator gives the person the choice of receiving the additional quantity of the product and paying for it or of receiving only the quantity of the product for which the executive officer is required to pay under section 18. O. Reg. 201/96, s. 21 (3); O. Reg. 459/06, s. 19 (3). (4) An operator of a pharmacy who supplies a listed drug product for an eligible person may charge a person other than the executive officer an amount equal to the amount otherwise payable by the executive officer under subsection 5 (1) or (3) of the Act if the person elects to pay the amount and, before the product is supplied, the person is advised that, subject to any co-payment, the product is available free of charge. O. Reg. 201/96, s. 21 (4); O. Reg. 459/06, s. 19 (4). (5) If the premises from which the operator of a pharmacy dispenses drugs are not electronically connected to the Health Network and, as a result, the operator does not submit claims by direct electronic transmission in accordance with section 24, the operator may charge, or accept payment from, a person other than the executive officer in respect of supplying a listed drug product for an eligible person in an amount equal to the amount that would have been payable by the executive officer were the operator entitled to be paid under subsection 5 (4) of the Act. O. Reg. 324/96, s. 3; O. Reg. 459/06, s. 19 (5). (6) In subsection (5), “Health Network” has the same meaning as in subsection 23 (1). O. Reg. 324/96, s. 3. 22. For the purposes of subsection 4 (2) of the Act, a physician may charge, or accept payment from, a person other than the executive officer in such amounts as may be charged by the operator of a pharmacy under subsection 4 (3), (4) or (5) of the Act or under section 21 of this Regulation. O. Reg. 201/96, s. 22; O. Reg. 459/06, s. 20. Miscellaneous 23. (1) In sections 24 to 30, “claim reversal” means a claim submitted to the executive officer to cancel a claim for payment that was previously submitted to the executive officer under the Act; (“annulation de demande”) “Health Network” means the electronic information retrieval system used by the Ministry to receive and process claims for payment under the Act; (“Système informatique des programmes de médicaments de l’Ontario”) “Manual” means the Ontario Drug Programs Reference Manual dated November 27, 2019, available on a website of the Ontario government, as amended from time to time. (“Manuel”) O. Reg. 201/96, s. 23 (1); O. Reg. 484/05, s. 3; O. Reg. 55/06, s. 2; O. Reg. 459/06, s. 21 (1); O. Reg. 436/19, s. 4. (2) For the purposes of sections 24 to 30, a claim for payment made under the Act does not include a claim reversal. O. Reg. 201/96, s. 23 (2). (3) For the purposes of sections 24 to 30, anything submitted to or done by the Minister before October 1, 2006 shall be deemed to have been submitted to or done by the executive officer. O. Reg. 459/06, s. 21 (2). 24. (1) An operator of a pharmacy or a physician who submits a claim for payment from the executive officer under the Act or a claim reversal shall submit the claim to the executive officer by direct electronic transmission via the Health Network. O. Reg. 201/96, s. 24 (1); O. Reg. 459/06, s. 22 (1). (2) Despite subsection (1), the following claims may be submitted on paper: 1. A claim for payment that is submitted to the executive officer more than seven days after the drug is supplied because proof that the drug is for an eligible person is not provided to the operator of the pharmacy or physician who supplied the drug until that time. 2. A claim reversal that is made more than 90 days after the day the original claim to which the claim reversal relates was submitted. 3. A claim for payment requiring more than two codes, as set out in the Manual. 4. A claim for payment by the executive officer in respect of supplying a listed drug product where the amount claimed is $10,000 or more. 5. A claim for payment for the supply of an extemporaneous preparation where the claim indicates that time spent on the compounding of the preparation was 100 minutes or more. 6. A claim for payment that is determined by the Ministry to be eligible for submission following a review by the Ministry or an inspection carried out under section 14 of the Act. 7. A claim for payment that is submitted in accordance with subsection 26 (3). O. Reg. 201/96, s. 24 (2); O. Reg. 324/96, s. 4; O. Reg. 574/99, s. 1; O. Reg. 55/06, s. 3 (1); O. Reg. 459/06, s. 22 (2, 3); O. Reg. 436/19, s. 5. (3) Except for claims submitted under paragraph 6 of subsection (2), claims for payment that are submitted on paper shall be submitted no more than six months from the day on which the service giving rise to the claim was provided. O. Reg. 55/06, s. 3 (2). 25. (1) A claim for payment from the executive officer under the Act shall contain the following information: 1. The bank identification number of the Ontario Drug Benefit Program, as assigned by the Canadian Payments Association. 2. The pharmacy claim standard version number used to transmit the claim. 3. The code for identifying the transaction as a claim for payment, as set out in the Manual. 4. The code for identifying the pharmacy’s or physician’s computer system, as set out in the Manual. 5. The code assigned by the software vendor to identify the version of the pharmacy’s or physician’s software. 6. The pharmacy identification code, as assigned by the executive officer to the pharmacy or the physician. 7. A number assigned to the transaction by the operator of a pharmacy or the physician. 8. The prescription number recorded on the prescription for the listed product supplied by the person dispensing the product. 9. The drug identification number of the listed drug product supplied or, in the case of a product other than a listed drug product, the product identification number assigned by the executive officer to the product supplied. 10. The Ontario drug benefit eligibility number together with any version code that may appear on the health card of the eligible person for whom the listed drug product was supplied. 11. The first and last names of the eligible person for whom the listed drug product was supplied. 12. The year, month and day on which the listed drug product was supplied. 13. The quantity of the listed drug product supplied. 14. The number of days of treatment contained in the prescription, as estimated by the operator of the pharmacy or the physician. 15. The drug cost amount or, if the acquisition cost of the drug is payable under the Act, the acquisition cost of the drug supplied. 16. The dispensing fee for supplying the drug and the mark up on the drug, if any. 17. The total amount claimed by the operator of the pharmacy or physician for the supplying of the drug. 18. Any other information that is necessary to process the amount payable on the claim. O. Reg. 201/96, s. 25 (1); O. Reg. 459/06, s. 23 (1-3); O. Reg. 320/07, s. 4 (1). (2) A claim for payment by the executive officer under the Act with respect to the supplying of an extemporaneous preparation for an eligible person shall include, in addition to the information required under subsection (1), the following information: 1. The drug benefit price or, if the acquisition cost of the ingredient is payable under the Act, the acquisition cost of each ingredient and the total costs of all the ingredients. 2. The length of time in minutes that was spent compounding the ingredients, not including the time required to dispense the preparation and the amount claimed for the time spent compounding the preparation. 3. The product identification number assigned by the executive officer to the extemporaneous preparation or, if there is no product identification number, i. the drug identification number of the ingredient used in the preparation that has the highest cost, and ii. the unlisted compound code assigned by the executive officer to the preparation, as set out in the Manual. O. Reg. 201/96, s. 25 (2); O. Reg. 459/06, s. 23 (4-6). (3) If an operator of a pharmacy or a physician makes a claim for payment of the acquisition cost of a listed drug product under subsection 6 (3) of the Act, the claim for payment with respect to the supplying of the listed drug product shall include, in addition to the information required under subsection (1), the following information: 1. The acquisition cost of the listed drug product in accordance with section 14. 2. The code for identifying the claim as being one to which subsection 6 (3) of the Act applies, as set out in the Manual. 3. Any other information that is necessary to calculate the cost to the operator of the pharmacy or the physician of the listed drug product. O. Reg. 201/96, s. 25 (3); O. Reg. 320/07, s. 4 (2). (4) If an operator of a pharmacy or a physician makes a claim for payment under the Act with respect to the supplying of a drug to which the executive officer has made the Act apply under section 16 of the Act, the claim shall include, in addition to the information required under subsection (1), the following information: 1. The drug cost amount of the drug as determined under section 15 of this Regulation. 2. Revoked: O. Reg. 320/07, s. 4 (4). 3. Any other information that is necessary to calculate the cost to the operator of the pharmacy or the physician of the drug. O. Reg. 201/96, s. 25 (4); O. Reg. 459/06, s. 23 (7-9); O. Reg. 320/07, s. 4 (3, 4). (5) If the operator of a pharmacy or a physician makes a claim for payment under the Act with respect to the supplying of a listed drug product pursuant to a prescription that contains a direction that there be no substitutions, the claim shall include, in addition to the information required under subsection (1), the following information: 1. The code for identifying the claim as being one to which subsection 6 (5) of the Act applies, as set out in the Manual. 2. Any other information that is necessary to calculate the cost to the operator of the pharmacy or the physician of the listed drug product. O. Reg. 201/96, s. 25 (5). (6) If the operator of a pharmacy or a physician makes a claim for payment on paper under subsection 24 (2), the claim shall be submitted on a form that is provided by the Ministry and is completed and signed by the operator of a pharmacy or by the physician, as the case may be, and shall include all the information required under subsection (1) other than the information referred to in paragraphs 1, 2, 4, 5 and 7 of that subsection and shall include the information required under subsections (2), (3), (4) and (5), if applicable. O. Reg. 201/96, s. 25 (6). 26. (1) In a claim reversal, the operator of a pharmacy or physician shall include the following information: 1. The code used to identify the claim as a claim reversal, as set out in the Manual. 2. The pharmacy claim standard version number used to transmit the claim, as set out in the Manual. 3. The information referred to in paragraphs 1, 2, 4, 5, 6, 7, 8, 10 and 12 of subsection 25 (1). 4. The intervention and exception code, if applicable, as set out in the Manual. O. Reg. 201/96, s. 26 (1). (2) If a claim reversal is made on paper under subsection 24 (2), the operator of the pharmacy or the physician, as the case may be, (a) shall submit the claim on a form provided by the Ministry, completed and signed by the operator of the pharmacy or the physician; and (b) despite paragraph 3 of subsection (1), shall not include the information referred to in paragraphs 1, 2, 4, 5 and 7 of subsection 25 (1) in the claim. O. Reg. 201/96, s. 26 (2). (3) If, after a claim for payment of the acquisition cost of a listed drug product under subsection 6 (3) of the Act is submitted, the acquisition cost of the listed drug product is varied as a result of a price reduction given to the operator of the pharmacy or the physician in respect of the listed drug product, the operator of the pharmacy or the physician, as the case may be, shall submit to the executive officer forthwith, (a) a claim reversal that includes the information required under subsection (1); and (b) a new claim for payment that includes a revised calculation of the cost of the listed drug product. O. Reg. 55/06, s. 4; O. Reg. 459/06, s. 24. 27. For the purposes of sections 11.1 and 11.2 of the Act, the following are prescribed conditions: 1. The operator of the pharmacy or the physician, as the case may be, must be a party to a subscription agreement with the Ministry whereby the operator or physician agrees to have the premises from which he or she dispenses drugs connected electronically to the Health Network and to submit all claims for payment under the Act via the Health Network. 2. The operator of the pharmacy or the physician must comply with the terms and conditions of the subscription agreement referred to in paragraph 1. 3. The operator of a pharmacy or the physician must comply with, i. the Act and its regulations, and ii. any other statute and its regulations related to the operation of a pharmacy or the practice of a physician including, without limitation and as applicable, the Drug Interchangeability and Dispensing Fee Act, the Drug and Pharmacies Regulation Act, the Narcotics Safety and Awareness Act, 2010, the Regulated Health Professions Act, 1991, the Pharmacy Act, 1991, the Medicine Act, 1991, the Personal Health Information Protection Act, 2004, the Food and Drugs Act (Canada), the Criminal Code (Canada), and the Controlled Drugs and Substances Act (Canada). 4. Without limiting the condition set out in paragraph 3, the operator of the pharmacy or the physician must not have committed an offence under the laws of Canada or Ontario related to fraud in the operation of the pharmacy or, in the case of a physician, in the practice of medicine. 5. The operator of the pharmacy or the physician must comply with the Manual. 6. The operator of the pharmacy or the physician must not submit any claims that the operator or physician knows or reasonably ought to know are false, inaccurate or misleading. O. Reg. 264/08, s. 2; O. Reg. 20/13, s. 3. 28. (1) An eligible person who is entitled to be paid by the executive officer under section 11.3 of the Act shall submit a claim for payment by the executive officer on paper. O. Reg. 201/96, s. 28 (1); O. Reg. 459/06, s. 26. (2) An eligible person who submits a claim under section 11.3 of the Act shall include the following information in the claim: 1. The name and full address of the person. 2. The receipt provided upon payment for the listed drug product. 3. The Ontario drug benefit eligibility number of the person. 4. The drug identification number of the listed drug product supplied. 5. The quantity of the listed drug product supplied. O. Reg. 201/96, s. 28 (2); O. Reg. 320/07, s. 5. 28.1 (1) If the operator of a pharmacy charges a person other than the executive officer an amount under subsection 21 (5) in respect of supplying a listed drug product, the eligible person for whom the product was supplied is entitled to be paid by the executive officer the amount that would have been paid to the operator of a pharmacy had the operator been entitled to payment under subsection 5 (4) of the Act. O. Reg. 324/96, s. 5; O. Reg. 459/06, s. 27. (2) An eligible person who is entitled to be paid under subsection (1) may submit a claim for payment on paper and the claim shall include the information set out in subsection 28 (2). O. Reg. 324/96, s. 5. (3) This section applies to an eligible person who submits a claim in respect of supplying a listed drug product for which a person was charged by a physician under section 22 in accordance with subsection 21 (5). O. Reg. 324/96, s. 5. 29. (1) Every operator of a pharmacy and physician shall retain the following records and maintain them for the period of time indicated in the Manual: 1. A copy of a statement of daily transaction totals prepared each day. 2. A copy of each summary remittance statement or reject statement received from the executive officer. 3. A copy of each record that is specified in the Manual as being required to support or validate a claim for payment or a claim reversal submitted under the Act. O. Reg. 196/21, s. 1. (2) The records referred to in subsection (1) shall be kept in, or be readily available to, (a) in the case of the operator of a pharmacy, the pharmacy or the dispensary of the pharmacy; or (b) in the case of a physician, the dispensary of the physician. O. Reg. 196/21, s. 1. 29.1 Revoked: O. Reg. 347/17, s. 4 (2). 30. Omitted (provides for coming into force of provisions of this Regulation). O. Reg. 201/96, s. 30. TABLE ANNUAL OUT-OF-POCKET EXPENSE TO BE EXCEEDED TO BECOME ELIGIBLE FOR TRILLIUM DRUG PROGRAM (in $500 increments) Annual Net Income ($ Dollars) Single Family of Two Family of Three Family over Three up to 6,500 350 250 200 150 6,501-7,000 353 253 203 153 7,001-7,500 359 259 209 159 7,501-8,000 364 264 214 164 8,001-8,500 370 270 220 170 8,501-9,000 376 276 226 176 9,001-9,500 381 281 231 181 9,501-10,000 387 287 237 187 10,001-10,500 393 293 243 193 10,501-11,000 398 298 248 198 11,001-11,500 404 304 254 204 11,501-12,000 410 310 260 210 12,001-12,500 415 315 265 215 12,501-13,000 421 321 271 221 13,001-13,500 427 327 277 227 13,501-14,000 432 332 282 232 14,001-14,500 438 338 288 238 14,501-15,000 444 344 294 244 15,001-15,500 449 349 299 249 15,501-16,000 455 355 305 255 16,001-16,500 461 361 311 261 16,501-17,000 466 366 316 266 17,001-17,500 472 372 322 272 17,501-18,000 478 378 328 278 18,001-18,500 483 383 333 283 18,501-19,000 489 389 339 289 19,001-19,500 495 395 345 295 19,501-20,000 500 400 350 300 20,001-20,500 511 411 361 311 20,501-21,000 534 434 384 334 21,001-21,500 556 456 406 356 21,501-22,000 579 479 429 379 22,001-22,500 601 501 451 401 22,501-23,000 624 524 474 424 23,001-23,500 646 546 496 446 23,501-24,000 669 569 519 469 24,001-24,500 691 591 541 491 24,501-25,000 714 614 564 514 25,001-25,500 736 636 586 536 25,501-26,000 759 659 609 559 26,001-26,500 781 681 631 581 26,501-27,000 804 704 654 604 27,001-27,500 826 726 676 626 27,501-28,000 849 749 699 649 28,001-28,500 871 771 721 671 28,501-29,000 894 794 744 694 29,001-29,500 916 816 766 716 29,501-30,000 939 839 789 739 30,001-30,500 961 861 811 761 30,501-31,000 984 884 834 784 31,001-31,500 1,006 906 856 806 31,501-32,000 1,029 929 879 829 32,001-32,500 1,051 951 901 851 32,501-33,000 1,074 974 924 874 33,001-33,500 1,096 996 946 896 33,501-34,000 1,119 1,019 969 919 34,001-34,500 1,141 1,041 991 941 34,501-35,000 1,164 1,064 1,014 964 35,001-35,500 1,186 1,086 1,036 986 35,501-36,000 1,209 1,109 1,059 1,009 36,001-36,500 1,231 1,131 1,081 1,031 36,501-37,000 1,254 1,154 1,104 1,054 37,001-37,500 1,276 1,176 1,126 1,076 37,501-38,000 1,299 1,199 1,149 1,099 38,001-38,500 1,321 1,221 1,171 1,121 38,501-39,000 1,344 1,244 1,194 1,144 39,001-39,500 1,366 1,266 1,216 1,166 39,501-40,000 1,389 1,289 1,239 1,189 40,001-40,500 1,411 1,311 1,261 1,211 40,501-41,000 1,434 1,334 1,284 1,234 41,001-41,500 1,456 1,356 1,306 1,256 41,501-42,000 1,479 1,379 1,329 1,279 42,001-42,500 1,501 1,401 1,351 1,301 42,501-43,000 1,524 1,424 1,374 1,324 43,001-43,500 1,546 1,446 1,396 1,346 43,501-44,000 1,569 1,469 1,419 1,369 44,001-44,500 1,591 1,491 1,441 1,391 44,501-45,000 1,614 1,514 1,464 1,414 45,001-45,500 1,636 1,536 1,486 1,436 45,501-46,000 1,659 1,559 1,509 1,459 46,001-46,500 1,681 1,581 1,531 1,481 46,501-47,000 1,704 1,604 1,554 1,504 47,001-47,500 1,726 1,626 1,576 1,526 47,501-48,000 1,749 1,649 1,599 1,549 48,001-48,500 1,771 1,671 1,621 1,571 48,501-49,000 1,794 1,694 1,644 1,594 49,001-49,500 1,816 1,716 1,666 1,616 49,501-50,000 1,839 1,739 1,689 1,639 50,001-50,500 1,861 1,761 1,711 1,661 50,501-51,000 1,884 1,784 1,734 1,684 51,001-51,500 1,906 1,806 1,756 1,706 51,501-52,000 1,929 1,829 1,779 1,729 52,001-52,500 1,951 1,851 1,801 1,751 52,501-53,000 1,974 1,874 1,824 1,774 53,001-53,500 1,996 1,896 1,846 1,796 53,501-54,000 2,019 1,919 1,869 1,819 54,001-54,500 2,041 1,941 1,891 1,841 54,501-55,000 2,064 1,964 1,914 1,864 55,001-55,500 2,086 1,986 1,936 1,886 55,501-56,000 2,109 2,009 1,959 1,909 56,001-56,500 2,131 2,031 1,981 1,931 56,501-57,000 2,154 2,054 2,004 1,954 57,001-57,500 2,176 2,076 2,026 1,976 57,501-58,000 2,199 2,099 2,049 1,999 58,001-58,500 2,221 2,121 2,071 2,021 58,501-59,000 2,244 2,144 2,094 2,044 59,001-59,500 2,266 2,166 2,116 2,066 59,501-60,000 2,289 2,189 2,139 2,089 60,001-60,500 2,311 2,211 2,161 2,111 60,501-61,000 2,334 2,234 2,184 2,134 61,001-61,500 2,356 2,256 2,206 2,156 61,501-62,000 2,379 2,279 2,229 2,179 62,001-62,500 2,401 2,301 2,251 2,201 62,501-63,000 2,424 2,324 2,274 2,224 63,001-63,500 2,446 2,346 2,296 2,246 63,501-64,000 2,469 2,369 2,319 2,269 64,001-64,500 2,491 2,391 2,341 2,291 64,501-65,000 2,514 2,414 2,364 2,314 65,001-65,500 2,536 2,436 2,386 2,336 65,501-66,000 2,559 2,459 2,409 2,359 66,001-66,500 2,581 2,481 2,431 2,381 66,501-67,000 2,604 2,504 2,454 2,404 67,001-67,500 2,626 2,526 2,476 2,426 67,501-68,000 2,649 2,549 2,499 2,449 68,001-68,500 2,671 2,571 2,521 2,471 68,501-69,000 2,694 2,594 2,544 2,494 69,001-69,500 2,716 2,616 2,566 2,516 69,501-70,000 2,739 2,639 2,589 2,539 70,001-70,500 2,761 2,661 2,611 2,561 70,501-71,000 2,784 2,684 2,634 2,584 71,001-71,500 2,806 2,706 2,656 2,606 71,501-72,000 2,829 2,729 2,679 2,629 72,001-72,500 2,851 2,751 2,701 2,651 72,501-73,000 2,874 2,774 2,724 2,674 73,001-73,500 2,896 2,796 2,746 2,696 73,501-74,000 2,919 2,819 2,769 2,719 74,001-74,500 2,941 2,841 2,791 2,741 74,501-75,000 2,964 2,864 2,814 2,764 75,001-75,500 2,986 2,886 2,836 2,786 75,501-76,000 3,009 2,909 2,859 2,809 76,001-76,500 3,031 2,931 2,881 2,831 76,501-77,000 3,054 2,954 2,904 2,854 77,001-77,500 3,076 2,976 2,926 2,876 77,501-78,000 3,099 2,999 2,949 2,899 78,001-78,500 3,121 3,021 2,971 2,921 78,501-79,000 3,144 3,044 2,994 2,944 79,001-79,500 3,166 3,066 3,016 2,966 79,501-80,000 3,189 3,089 3,039 2,989 80,001-80,500 3,211 3,111 3,061 3,011 80,501-81,000 3,234 3,134 3,084 3,034 81,001-81,500 3,256 3,156 3,106 3,056 81,501-82,000 3,279 3,179 3,129 3,079 82,001-82,500 3,301 3,201 3,151 3,101 82,501-83,000 3,324 3,224 3,174 3,124 83,001-83,500 3,346 3,246 3,196 3,146 83,501-84,000 3,369 3,269 3,219 3,169 84,001-84,500 3,391 3,291 3,241 3,191 84,501-85,000 3,414 3,314 3,264 3,214 85,001-85,500 3,436 3,336 3,286 3,236 85,501-86,000 3,459 3,359 3,309 3,259 86,001-86,500 3,481 3,381 3,331 3,281 86,501-87,000 3,504 3,404 3,354 3,304 87,001-87,500 3,526 3,426 3,376 3,326 87,501-88,000 3,549 3,449 3,399 3,349 88,001-88,500 3,571 3,471 3,421 3,371 88,501-89,000 3,594 3,494 3,444 3,394 89,001-89,500 3,616 3,516 3,466 3,416 89,501-90,000 3,639 3,539 3,489 3,439 90,001-90,500 3,661 3,561 3,511 3,461 90,501-91,000 3,684 3,584 3,534 3,484 91,001-91,500 3,706 3,606 3,556 3,506 91,501-92,000 3,729 3,629 3,579 3,529 92,001-92,500 3,751 3,651 3,601 3,551 92,501-93,000 3,774 3,674 3,624 3,574 93,001-93,500 3,796 3,696 3,646 3,596 93,501-94,000 3,819 3,719 3,669 3,619 94,001-94,500 3,841 3,741 3,691 3,641 94,501-95,000 3,864 3,764 3,714 3,664 95,001-95,500 3,886 3,786 3,736 3,686 95,501-96,000 3,909 3,809 3,759 3,709 96,001-96,500 3,931 3,831 3,781 3,731 96,501-97,000 3,954 3,854 3,804 3,754 97,001-97,500 3,976 3,876 3,826 3,776 97,501-98,000 3,999 3,899 3,849 3,799 98,001-98,500 4,021 3,921 3,871 3,821 98,501-99,000 4,044 3,944 3,894 3,844 99,001-99,500 4,066 3,966 3,916 3,866 99,501-100,000 4,089 3,989 3,939 3,889 O. Reg. 201/96, Table; O. Reg. 83/98, s. 5. Schedule 1 Revoked: O. Reg. 508/96, s. 3. Schedule 2 1. Insulin 2. Adrenocorticotrophic hormones 3. Nitrate vasodilators O. Reg. 201/96, Sched. 2. Schedule 3 Revoked: O. Reg. 220/10, s. 6. Schedule 4 Revoked: O. Reg. 459/06, s. 29.